US20140274990A1 - Ceftolozane pharmaceutical compositions - Google Patents
Ceftolozane pharmaceutical compositions Download PDFInfo
- Publication number
- US20140274990A1 US20140274990A1 US14/212,781 US201414212781A US2014274990A1 US 20140274990 A1 US20140274990 A1 US 20140274990A1 US 201414212781 A US201414212781 A US 201414212781A US 2014274990 A1 US2014274990 A1 US 2014274990A1
- Authority
- US
- United States
- Prior art keywords
- ceftolozane
- sodium chloride
- pharmaceutical composition
- composition
- sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- KHXMKUIQYAJGBA-UHFFFAOYSA-N CCCNC(=O)NC1=C(N)N(C)N=C1 Chemical compound CCCNC(=O)NC1=C(N)N(C)N=C1 KHXMKUIQYAJGBA-UHFFFAOYSA-N 0.000 description 1
- WCKVTVIEDQMALA-RIAQUSEWSA-N CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC1=C(C(=O)O)N2C(=O)[C@@H](CC(=O)/C(=N\OC(C)(C)C(=O)O)C3=NSC(N)=N3)[C@H]2SC1.O=[SH](=O)O[O-] Chemical compound CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC1=C(C(=O)O)N2C(=O)[C@@H](CC(=O)/C(=N\OC(C)(C)C(=O)O)C3=NSC(N)=N3)[C@H]2SC1.O=[SH](=O)O[O-] WCKVTVIEDQMALA-RIAQUSEWSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
Definitions
- This disclosure relates to pharmaceutical compositions comprising ceftolozane.
- Ceftolozane is a cephalosporin antibacterial agent, also referred to as CXA-101, FR264205, or by chemical names such as (6R,7R)-3-[(5-amino-4- ⁇ [(2-aminoethyl)carbamoyl]amino ⁇ -1-methyl-1H-pyrazol-2-ium-2-yl)methyl]-7-( ⁇ (2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl ⁇ amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, and 7 ⁇ -[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3- ⁇ 3-amino-4-
- ceftolozane salts are examples of ceftolozane salts.
- a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt [e.g., sodium salt, potassium salt, etc.], an alkaline earth metal salt [e.g., calcium salt, magnesium salt, etc.], an ammonium salt; a salt with an organic base, for example, an organic amine salt [e.g., trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N′-dibenzylethylenediamine salt, etc.]; an inorganic acid addition salt [e.g., hydrochloride, hydrobromide, sulfate, hydrogen sulfate, phosphate, etc.]
- an inorganic acid addition salt e.g., hydrochloride, hydrobromide, sulfate
- ceftolozane is useful as antibiotics for the treatment of certain serious infections, including serious complicated intra-abdominal infections and complicated urinary tract infections.
- the ceftolozane pharmaceutical compositions can be administered as intravenous antibacterial agents to treat these infection.
- the antibacterial activity of ceftolozane is believed to result from its interaction with penicillin binding proteins (PBPs) to inhibit the biosynthesis of the bacterial cell wall which acts to stop bacterial replication.
- Antibacterial pharmaceutical compositions can include a therapeutically effective unit dose of a pharmaceutically acceptable salt of ceftolozane formulated for intravenous administration.
- ceftolozane was unstable in certain lyophilized pharmaceutical compositions initially evaluated for intravenous administration.
- a decrease in ceftolozane purity and the formation of multiple additional related substances were detected in certain initial ceftolozane pharmaceutical compositions by peaks in high purity liquid chromatography (HPLC) after stability testing.
- HPLC high purity liquid chromatography
- ceftolozane and other commonly used additives may be included in pharmaceutical compositions comprising ceftolozane or many other cephalosporin compounds “if needed.”
- the disclosure does not disclose a reduction in ceftolozane purity in pharmaceutical compositions containing ceftolozane sulfate, or the formation of additional related substances observed during stability testing.
- this disclosure provide guidance on the formation of ceftolozane pharmaceutical compositions to increase ceftolozane purity during stability testing or control the relative amounts of ceftolozane related substances detected by HPLC peak formation during stability testing.
- the pharmaceutical antibiotic compositions can include ceftolozane sulfate obtained by a process comprising the steps of lyophilizing an aqueous solution containing ceftolozane and a stabilizing amount of sodium chloride, where the stabilizing amount of sodium chloride is about 125 to 500 mg of sodium chloride (including, e.g., 480-500 mg) per 1,000 mg ceftolozane active in the aqueous solution prior to lyophilization.
- HPLC high performance liquid chromatography
- lyophilized ceftolozane compositions having 125 mg or more sodium chloride relative to the fixed amount of 1,000 mg ceftolozane active in an aqueous solution prior to lyophilization produced lyophilized compositions having lower quantities of additional substances identified by peaks 1 and 7 having characteristic retention times measured by HPLC relative to the retention time of ceftolozane.
- HPLC measurements reported herein refer to HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250 ⁇ 4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH 3 CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C.
- the retention time of peaks 1 and 7 are about ⁇ 0.1 and about 1.3 relative to ceftolozane (an “RRT of 0.1 and 1.3, respectively).
- sodium chloride stabilized ceftolozane compositions described in Example 3 were characterized by about 37-94% less of the material of peak 1 and about 38-306% less of the material of peak 7 (measured by corresponding HPLC peak areas) than comparable ceftolozane compositions having less than 125 mg sodium chloride (e.g., see 7-day stability study in Example 3).
- the disclosed sodium chloride stabilized ceftolozane compositions can be characterized by decrease in ceftolozane total purity is not greater than 4.06% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250 ⁇ 4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH 3 CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C.
- preferred pharmaceutical compositions contain ceftolozane sulfate having an improved stability as a decrease in the rate of ceftolozane purity and/or a decrease in the rate of formation of substances characterized by HPLC peaks 1 and 7 identified during a 7-day stability study in Example 3.
- FIGS. 1A and 1B are chromatograms of CXA-101 ceftolozane drug substance obtained from the lyophilization process of Example 1. The chromatograms were obtained according to the analytical method described in Example 2.
- FIG. 2 is a diagram of a lyophilization process for the ceftolozane obtained according to the process described in Example 1.
- FIG. 3 is a table (Table 1) of peaks for the ceftolozane prepared by the lyophilization process in Example 1 obtained by HPLC according to the analytical method of Example 2.
- FIG. 4 is a table (Table 2) showing the composition of various additional ceftolozane pharmaceutical compositions in which the sodium chloride content is varied.
- FIG. 5A is a table (Table 3) showing the total purity of ceftolozane in the pharmaceutical compositions of FIG. 4 , as measured by HPLC peak area according to the analytical method of described in Example 2.
- FIG. 5B is a graph showing the total purity of certain pharmaceutical compositions disclosed in FIG. 4 , as measured by HPLC peak area.
- FIG. 6A is a table (Table 4) showing the amount of material from characteristic peak 1 in the pharmaceutical compositions of FIG. 4 , as measured by HPLC peak area according to the analytical method of described in Example 2.
- FIG. 6B is a graph showing the amount of material from characteristic peak 1 in the pharmaceutical compositions of FIG. 4 , as measured by HPLC peak area according to the analytical method of described in Example 2.
- FIG. 7A is a table (Table 5) showing the amount of material from characteristic peak 3 in the pharmaceutical compositions of FIG. 4 , as measured by HPLC peak area according to the analytical method of described in Example 2.
- FIG. 7B is a graph showing the amount of material from characteristic peak 3 in the pharmaceutical compositions of FIG. 4 , as measured by HPLC peak area according to the analytical method of described in Example 2.
- FIG. 8A is a table (Table 6) showing the amount of material from characteristic peak 7 in the pharmaceutical compositions of FIG. 4 , as measured by HPLC peak area according to the analytical method of described in Example 2.
- FIG. 8B is a graph showing the amount of material from characteristic peak 7 in the pharmaceutical compositions of FIG. 4 , as measured by HPLC peak area according to the analytical method of described in Example 2.
- FIG. 9A is a table (Table 7) showing the formulation composition of the Co-Lyo-Combo Drug Product used in Example 4A.
- FIG. 9B is a table (Table 8) showing impurity concentrations at time zero, one month and three months at 25° C./60% relative humidity of the Co-Lyo-Combo Drug Product.
- FIG. 9C is a table (Table 9) showing impurity concentrations at time zero, one month and three months at 40° C./75% relative humidity of the Co-Lyo-Combo Drug Product.
- FIG. 10A is a table (Table 10) showing the formulation composition of the Blend Drug Product used in Example 4B.
- FIG. 10B is a table (Table 11) showing impurity concentrations at time zero, one month and three months at 25° C./60% relative humidity of the Blend Drug Product used in Example 4B.
- FIG. 10C is a table (Table 12) showing impurity concentrations at time zero, one month and three months at 40° C./75% relative humidity of the Blend Drug Product used in Example 4B.
- FIG. 11 is a table (Table 13) showing the composition of various ceftolozane pharmaceutical compositions in which the sodium chloride concentration is varied.
- FIG. 12 is a table (Table 14) showing the purity of Ceftolozane in CXA-201 Compositions with varying amounts of sodium from sodium chloride at time zero, 1 day, 3 days and 7 days at at 30° C. and 60° C.
- FIG. 13 is a table (Table 15) showing the HPLC area of Impurity of Peak 1 in CXA-201 Compositions with varying amounts of sodium from sodium chloride at time zero, 1 day, 3 days and 7 days at 30° C. and at 60° C.
- FIG. 14 is a table (Table 16) showing the HPLC area of the Impurity at RRT 0.43 and Impurity Peak 3 in CXA-201 Compositions with varying amounts of sodium from sodium chloride at time zero, 1 day, 3 days and 7 days at 30° C. and at 60° C.
- FIG. 15 is a table (Table 17) showing the HPLC area of Impurity of Peak 7 in CXA-201 Compositions with varying amounts of sodium from sodium chloride at time zero, 1 day, 3 days and 7 days at 30° C. and at 60° C.
- FIG. 16 is a table (Table 18) showing the finished drug product unit composition of ceftolozane/tazolactam.
- FIG. 17 is a table (Table 19) showing the primary container closure system for the ceftolozane/tazobactam unit product.
- Ceftolozane sulfate can be stabilized in lyophilized pharmaceutical compositions by incorporation of a stabilizing-effective amount of an inorganic salt stabilizing agent in a solution that can be lyophilized to obtain a lyophilized composition containing stabilized ceftolozane.
- the stabilizing-effective amount of a sodium chloride inorganic salt stabilizing agent is preferably 125 mg to 500 mg (preferably about 480-500 mg) of sodium chloride per 1,000 mg of ceftolozane active.
- compositions comprising ceftolozane and stabilizing amount of sodium chloride can be obtained by lyophilization of a solution comprising a stabilizing-effective amount of sodium chloride and ceftolozane sulfate.
- lyophilization is a process of freeze-drying in which water is sublimed from a frozen solution of one or more solutes. Specific methods of lyophilization are described in Remington's Pharmaceutical Sciences, Chapter 84, page 1565, Eighteenth Edition, A. R. Gennaro, (Mack Publishing Co., Easton, Pa., 1990).
- a pharmaceutical composition comprising ceftolozane can be prepared by adding a stabilizing amount of sodium chloride in a fixed ratio to ceftolozane in an aqueous solution prior to lyophilization, then lyophilizing the solution to obtain a lyophilized composition comprising sodium chloride and ceftolozane.
- the pharmaceutical antibiotic compositions can include ceftolozane sulfate obtained by a process comprising the steps of lyophilizing an aqueous solution containing ceftolozane and a stabilizing amount of sodium chloride, where the stabilizing amount of sodium chloride is about 125 to 500 mg (preferably, 480-500 mg) of sodium chloride per 500 mg ceftolozane active in the aqueous solution prior to lyophilization.
- the pharmaceutical compositions comprising ceftolozane disclosed herein can be prepared by adding 125 to 500 mg (preferably, 480-500 mg) sodium chloride per 1000 mg of ceftolozane prior to lyophilization (or spray drying).
- the pharmaceutical compositions can be obtained by a method comprising the steps of adding a stabilizing amount (e.g., 125 to 500 mg [more preferably, 480-500 mg] sodium chloride per 1000 mg of ceftolozane active) followed by lyophilizing (or spray drying) the composition comprising the sodium chloride and ceftolozane.
- a stabilizing amount e.g., 125 to 500 mg [more preferably, 480-500 mg] sodium chloride per 1000 mg of ceftolozane active
- ceftolozane and a stabilizing amount of sodium chloride can be dissolved in an aqueous solution that can be lyophilized (or spray drying) to obtain a ceftolozane pharmaceutical composition.
- the pharmaceutical compositions may comprise other additional components including stabilizers, pH adjusting additives (e.g., buffers) and the like.
- these additives include sodium chloride, citric acid and L-arginine.
- the pharmaceutical antibiotic compositions can include ceftolozane sulfate obtained by a process comprising the steps of lyophilizing an aqueous solution containing ceftolozane sulfate with a stabilizing amount of sodium chloride (e.g., 125 to 500 mg [more preferably, 480-500 mg] of sodium chloride per 1,000 mg ceftolozane active), with L-arginine and/or citric acid in the aqueous solution prior to lyophilization.
- a stabilizing amount of sodium chloride e.g., 125 to 500 mg [more preferably, 480-500 mg] of sodium chloride per 1,000 mg ceftolozane active
- the use of sodium chloride results in greater ceftolozane stability, while an amount of L-arginine can be used that is effective to adjust pH and to increase the solubility of ceftolozane, and citric acid can be included in an amount effective to reduce or prevent discoloration of the product, due to its ability to chelate metal ions.
- the aqueous solution can be subsequently lyophilized (or spray dried) to obtain a stabilized lyophilized ceftolozane sulfate composition comprising ceftolozane sulfate, sodium chloride, L-arginine and citric acid.
- the pharmaceutical composition can also be a Ceftolozane/Tazobactam for Injection Drug Product, 1000 mg/500 mg. It is presented as a combination of two sterile active powders in a single vial intended for reconstitution and intravenous infusion.
- the drug product is first prepared by converting ceftolozane sulfate drug substance to a sterile drug product intermediate (DPI) powder with excipients citric acid, sodium chloride and L-arginine. This is commonly done by lyophilization, as described above. Tazobactam sodium drug substance is presented as a sterile powder without any excipients. The tazobactam sodium drug substance is typically lyophilized (or spray dried). The drug product is then prepared by aseptically filling the two powders (e.g., the two separately lyophilized drug powders or spray dried powders) sequentially into a single vial.
- DPI sterile drug product intermediate
- Each vial of ceftolozane/tazobactam for injection contains approximately 2255 mg ceftolozane sterile DPI powder that contains 1147 mg ceftolozane sulfate, which is equivalent to 1000 mg ceftolozane free base, as well as approximately 537 mg tazobactam sodium sterile drug substance, equivalent to 500 mg tazobactam free acid.
- the vial is reconstituted with 10 mL vehicle, 5% Dextrose Injection USP, sterile Water for Injection or 0.9% Sodium Chloride Injection USP, then the vial contents further diluted in an infusion bag of 0.9% Sodium Chloride Injection USP or 5% Dextrose Injection USP, for administration.
- the constituents are shown in Table 18, FIG. 16 .
- the primary container-closure system is a Type 1 20 mL molded glass vial with 20 mm neck finish. The vial is sealed by a 20 mm rubber stopper and 20 mm plastic flip-cap seal with aluminum ferrule.
- the primary contain-closure system used for the ceftolozane/tazobactam unit product is summarized in Table 19, FIG. 17 .
- compositions comprising ceftolozane can be obtained by methods that include the steps of: (1) adding a stabilizing amount of sodium chloride to ceftolozane (or preparing an aqueous solution of sodium chloride and ceftolozane) optionally followed by co-lyophilizing or spray drying the ceftolozane and sodium chloride (or aqueous solution thereof); and (2) combining the product of step (1) with other components.
- the product of step (1) can be combined with a ⁇ -lactamase inhibitor, such as tazobactam (CAS#: 89786-04-9), avibactam (CAS#1192500-31-4), Sulbactam (CAS#68373-14-8) and/or clavulanate (CAS#58001-44-8).
- a ⁇ -lactamase inhibitor such as tazobactam (CAS#: 89786-04-9), avibactam (CAS#1192500-31-4), Sulbactam (CAS#68373-14-8) and/or clavulanate (CAS#58001-44-8).
- the beta lactamase inhibitor can be included in a crystalline or amorpous form, such as a lyophilized tazobactam or crystalline tazobactam (e.g., U.S. Pat. Nos. 8,476,425 and 5,763,603) to obtain the pharmaceutical composition.
- the stabilizing effect of sodium chloride on ceftolozane can be measured by high performance liquid chromatography (HPLC) analysis, for example by detecting the ratio of peak areas obtained for ceftolozane compared to peaks for other substances.
- HPLC high performance liquid chromatography
- Various ceftolozane compositions having 50-481 mg of sodium chloride per 1,000 mg ceftolozane active as described in Table 2 ( FIG. 4 ) were tested for stability as described in Example 3.
- the stability testing of lyophilized ceftolozane pharmaceutical compositions revealed improved ceftolozane stability in compositions formed from aqueous solutions having at least 125 mg sodium chloride.
- HPLC measurements reported herein are obtained using a Develosil column ODS-UG-5; 5 micrometers; 250 ⁇ 4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH 3 CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C.
- lyophilized ceftolozane compositions having 125 mg more sodium chloride relative to the fixed amount of ceftolozane prior to lyophilization were about 35-90% more stable than comparable ceftolozane compositions having less than 125 mg sodium chloride, as measured by total ceftolozane purity during a 7-day stability study in Example 3.
- the total purity of ceftolozane was measured by the % decrease in the ceftolozane HPLC peak during the 7-day stability test.
- samples obtained by lyophilizing compositions containing 125 mg, 190 mg and 481 mg of sodium chloride per 1,000 mg of ceftolozane active showed a decrease in ceftolozane that was at least about 35% less than reductions in ceftolozane observed for formulations containing 50 mg or 75 mg sodium chloride per 1,000 mg ceftolozane active (e.g., the % decrease in ceftolozane for the sample containing 75 mg sodium chloride was about 35% greater than the comparable % decrease in ceftolozane for the sample containing 190 mg sodium chloride).
- samples obtained by lyophilizing compositions containing 125 mg, 190 mg and 481 mg of sodium chloride per 1,000 mg of ceftolozane active showed a decrease in ceftolozane that was up to about 90% less than reductions in ceftolozane observed for forulations containing 50 mg or 75 mg sodium chloride per (e.g., the % decrease in ceftolozane for the sample containing 50 mg sodium chloride was about 90% greater than the comparable % decrease in ceftolozane for the sample containing 481 mg sodium chloride).
- lyophilized ceftolozane compositions having 125 mg more sodium chloride relative to the fixed amount of 1,000 mg ceftolozane active in an aqueous solution prior to lyophilization produced lyophilized compositions having lower quantities of additional substances identified by peaks 1 and 7 having characteristic retention times measured by HPLC (see Table 1, FIG. 3 , indicating retention times of about 0.1 for peak 1 and about 1.3 for peak 7 relative to celftolozane measured according to the HPLC method of Example 2).
- these sodium chloride stabilized ceftolozane compositions were characterized by about 37-94% less of the material of peak 1 and about 38-306% less of the material of peak 7 (measured by corresponding HPLC peak areas) than comparable ceftolozane compositions having less than 125 mg sodium chloride (e.g., see 7-day stability study in Example 3).
- the amount of the composition of peak 1 was measured by the % increase in the peak 1 HPLC peak during the 7-day stability test of Example 3.
- samples obtained by lyophilizing compositions containing 125 mg, 190 mg and 481 mg of sodium chloride per 1,000 mg of ceftolozane active showed at least a 37% reduction in the amount of the peak 1 composition observed for these formulations containing at least 125 mg sodium chloride per 1,000 mg ceftolozane active, compared to the compositions obtained by lyophilizing 50 mg or 75 mg sodium chloride per 1,000 mg of ceftolozane active (e.g., the % increase in peak 1 for the sample containing 75 mg sodium chloride was about 37% greater than the comparable % decrease in ceftolozane for the sample containing 190 mg sodium chloride).
- samples obtained by lyophilizing compositions containing 125 mg, 190 mg and 481 mg of sodium chloride per 1,000 mg of ceftolozane active showed up to a 94% reduction in the amount of the peak 1 composition observed for these formulations containing at least 125 mg sodium chloride per 1,000 mg ceftolozane active, compared to the compositions obtained by lyophilizing 50 mg or 75 mg sodium chloride per 1,000 mg of ceftolozane active (e.g., the % increase in peak 1 for the sample containing 50 mg sodium chloride was about 94% greater than the comparable % decrease in ceftolozane for the sample containing 481 mg sodium chloride).
- the amount of the composition of peak 3 was measured by the % increase in the peak 1 HPLC peak during the 7-day stability test of Example 3.
- samples obtained by lyophilizing compositions containing 125 mg and 190 mg of sodium chloride per 1,000 mg of ceftolozane active showed at least a 269% reduction in the amount of the peak 3 composition observed for these formulations containing at least 125 mg sodium chloride per 1,000 mg ceftolozane active, compared to the compositions obtained by lyophilizing 50 mg or 75 mg sodium chloride per 1,000 mg of ceftolozane active (e.g., the % increase in peak 3 for the sample containing 50 mg sodium chloride was about 269% greater than the comparable % decrease in ceftolozane for the sample containing 190 mg sodium chloride).
- samples obtained by lyophilizing compositions containing 125 mg or 190 mg of sodium chloride per 1,000 mg of ceftolozane active showed up to a 333% reduction in the amount of the peak 3 composition observed for these formulations containing at least 125 mg sodium chloride per 1,000 mg ceftolozane active, compared to the compositions obtained by lyophilizing 50 mg or 75 mg sodium chloride per 1,000 mg of ceftolozane active (e.g., the % increase in peak 3 for the sample containing 75 mg sodium chloride was about 333% greater than the comparable % decrease in ceftolozane for the sample containing 125 mg sodium chloride).
- the ceftolozane sample containing 481 mg of sodium chloride had a higher amount of the composition of peak 3 than the ceftolozane samples containing 50 mg or 75 mg of sodium chloride.
- the amount of the composition of peak 7 was measured by the % increase in the peak 7 HPLC peak during the 7-day stability test of Example 3.
- samples obtained by lyophilizing compositions containing 125 mg, 190 mg and 481 mg of sodium chloride per 1,000 mg of ceftolozane active showed at least a 38% reduction in the amount of the peak 7 composition observed for these formulations containing at least 125 mg sodium chloride per 1,000 mg ceftolozane active, compared to the compositions obtained by lyophilizing 50 mg or 75 mg sodium chloride per 1,000 mg of ceftolozane active (e.g., the % increase in peak 7 for the sample containing 75 mg sodium chloride was about 38% greater than the comparable % decrease in ceftolozane for the sample containing 125 mg sodium chloride).
- samples obtained by lyophilizing compositions containing 125 mg, 190 mg and 481 mg of sodium chloride per 1,000 mg of ceftolozane active showed up to a 306% reduction in the amount of the peak 7 composition observed for these formulations containing at least 125 mg sodium chloride per 1,000 mg ceftolozane active, compared to the compositions obtained by lyophilizing 50 mg or 75 mg sodium chloride per 1,000 mg of ceftolozane active (e.g., the % increase in peak 7 for the sample containing 50 mg sodium chloride was about 306% greater than the comparable % decrease in ceftolozane for the sample containing 481 mg sodium chloride).
- preferred pharmaceutical compositions contain ceftolozane sulfate having an improved stability as a decrease in the rate of ceftolozane purity and/or a decrease in the rate of formation of substances characterized by HPLC peaks 1 and 7 identified during a 7-day stability study in Example 3.
- the preferred ceftolozane pharmaceutical compositions comprise a stabilizing amount of sodium chloride (e.g., 125 to 500 mg of sodium chloride per 1000 mg of ceftolozane).
- Certain preferred compositions demonstrate improved ceftolozane purity (e.g., Table 3 in FIG. 5A ) and chemical stability (e.g., with respect to the composition of HPLC peak 1 in Table 4, FIG. 6A ) compared pharmaceutical compositions comprising ceftolozane with comparatively less sodium chloride.
- compositions comprising ceftolozane can be formulated to treat infections by parenteral administration (including subcutaneous, intramuscular, and intravenous) administration.
- Pharmaceutical compositions may additionally comprise excipients, stabilizers, pH adjusting additives (e.g., buffers) and the like.
- pH adjusting additives e.g., buffers
- Non-limiting examples of these additives include sodium chloride, citric acid and L-arginine.
- the use of sodium chloride results in greater stability; L-arginine is used to adjust pH and to increase the solubility of ceftolozane; and citric acid is used to prevent discoloration of the product, due to its ability to chelate metal ions.
- the pharmaceutical compositions described herein are formulated for administration by intravenous injection or infusion.
- Pharmaceutical antibiotic compositions can include ceftolozane sulfate and stabilizing amount of sodium chloride (e.g., 125 to 500 mg of sodium chloride per 1,000 mg ceftolozane active) in a lyophilized unit dosage form (e.g., powder in a vial).
- the unit dosage form can be dissolved with a pharmaceutically acceptable carrier, and then intravenously administered.
- pharmaceutical antibiotic compositions can include ceftolozane sulfate obtained by a process comprising the steps of lyophilizing an aqueous solution containing ceftolozane and a stabilizing amount of sodium chloride, where the stabilizing amount of sodium chloride is about 125 to 500 mg of sodium chloride per 1,000 mg ceftolozane active in the aqueous solution prior to lyophilization.
- a method for the treatment of bacterial infections in a mammal comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition prepared according to the methods described herein.
- a method for the treatment of bacterial infections in a mammal can comprise administering to said mammal a therapeutically effective amount of a pharmaceutical composition comprising ceftolozane sulfate and sodium chloride.
- Non-limiting examples of bacterial infections that can be treated by the methods of the invention include infections caused by: aerobic and facultative gram-positive microorganisms (e.g., Staphylococcus aureus, Enterococcus faecalis, Staphylococcus epidermidis, Streptococcus agalactiae, Streptococcus pneumonia, Streptococcus pyogenes, Viridans group streptococci), aerobic and facultative gram-negative microorganisms (e.g., Acinetobacter baumanii, Escherichia coli, Haemophilus influenza, Klebsiella pneumonia, Pseudomonas aeruginosa, Citrobacter koseri, Moraxella catarrhalis, Morganella morganii, Neisseria gonorrhoeae, Proteus mirabilis, Proteus vulgaris, Serratia marcescens, Providencia stuartii,
- bacterial infection is associated with one or more of the following conditions: complicated intra-abdominal infections, complicated urinary tract infections (cUTIs) and pneumonia (e.g., community-acquired, or nosocomial pneumonia).
- cUTIs complicated intra-abdominal infections
- pneumonia e.g., community-acquired, or nosocomial pneumonia.
- Community-acquired pneumonia can include infections caused by piperacillin-resistant, beta-lactamase producing strains of Haemophilus influenza .
- Nosocomial pneumonia caused by piperacillin-resistant, beta-lactamase producing strains of Staphylococcus aureus and by Acinetobacter baumanii, Haemophilus influenzae, Klebsiella pneumoniae , and Pseudomonas aeruginosa.
- treating describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of a pharmaceutical composition of the present invention to alleviate the symptoms or complications of a disease, condition or disorder, or to reduce the extent of the disease, condition or disorder.
- the term “treat” can also include treatment of a cell in vitro or an animal model.
- a “therapeutically effective amount” of a compound of the invention is meant a sufficient amount of the compound to treat the disorder (e.g., bacterial infection).
- the specific therapeutically effective amount that is required for the treatment of any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound or composition employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts (see, for example, Goodman and Gilman's, “The Pharmacological Basis of Therapeutics”, Tenth Edition, A.
- 125-500 mg sodium chloride per 1000 mg of ceftolozane refers to a ratio of sodium chloride to ceftolozane active.
- the phrase “125-500 mg sodium chloride per 1000 mg of ceftolozane” includes “62.5 to 250 mg sodium chloride per 500 mg of ceftolozane active” and other similar weight ratios.
- 1,000 mg of ceftolozane as ceftolozane sulfate refers to an amount of ceftolozane sulfate effective to provide 1,000 mg of ceftolozane.
- the amount of sodium per gram of ceftolozane activity in a pharmaceutical composition containing ceftolozane sulfate and sodium chloride can be calculated using the relevant molecular weights of ceftolozane, ceftolozane sulfate, sodium chloride and sodium.
- 1000 mg ceftolozane refers to an amount of ceftolozane that is considered a bioequivalent by the United States Food and Drug Administration (FDA), i.e. for which 90% CI of the relative mean Cmax, AUC(0-t) and AUC(0- ⁇ ) is within 80.00% to 125.00% of the reference formulation in the fasting state (see: “Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations”. Center for Drug Evaluation and Research, United States Food and Drug Administration, 2003).
- FDA United States Food and Drug Administration
- Ceftolozane active refers to the active portion of a salt form of ceftolozane, i.e., the free base form of ceftolozane.
- the disclosed sodium chloride stabilized ceftolozane compositions can be characterized by decrease in ceftolozane total purity is not greater than 3.7% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250 ⁇ 4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH 3 CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C.
- the disclosed sodium chloride stabilized ceftolozane compositions can be characterized by decrease in ceftolozane total purity is not greater than 4.2% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250 ⁇ 4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH 3 CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C.
- the disclosed sodium chloride stabilized ceftolozane compositions can be characterized by decrease in ceftolozane total purity is not greater than 4.5% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250 ⁇ 4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH 3 CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C.
- the disclosed sodium chloride stabilized ceftolozane compositions can be characterized by decrease in ceftolozane total purity is not greater than 5.0% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250 ⁇ 4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH 3 CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C.
- the disclosed sodium chloride stabilized ceftolozane compositions were characterized by an increase in the amount of the impurity represented by Peak 1 not greater than 1.8% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250 ⁇ 4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH 3 CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C., where Peak 1 has a retention time relative to ceftolozane of 0.1.
- the disclosed sodium chloride stabilized ceftolozane compositions were characterized by an increase in the amount of the impurity represented by Peak 1 not greater than 2.0% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250 ⁇ 4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH 3 CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C., where Peak 1 has a retention time relative to ceftolozane of 0.1.
- the disclosed sodium chloride stabilized ceftolozane compositions were characterized by an increase in the amount of the impurity represented by Peak 1 not greater than 2.2% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250 ⁇ 4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH 3 CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C., where Peak 1 has a retention time relative to ceftolozane of 0.1.
- CXA-101 bulk drug product manufacturing process There are four main steps in the manufacture of CXA-101 bulk drug product: dissolution, sterile filtration, bulk lyophilization, and packaging into Sterbags®. These four main steps are composed of a total of 20 minor steps.
- the CXA-101 bulk drug product manufacturing process is presented below.
- WFI water for injection
- Solution pH is verified to be in the target range of 6.5 to 7.0.
- a prescribed amount of sodium chloride is added to the solution, wherein the preferred amount of sodium chloride is 125-500 mg of sodium chloride per 1000 mg of ceftolozane active.
- Solution pH is verified to be in the target range of 6.0 to 7.0. If the pH is out of this range adjust with either L-Arginine or citric acid.
- the solution is passed through the filter (pore size 0.45 ⁇ m) followed by double filters (pore size 0.22 ⁇ m) onto a shelf on the Criofarma lyophilizer.
- the washing solution is passed from Step 12 through sterile filtration.
- the washing solution is loaded onto a separate shelf in the lyophilizer (and later discarded).
- the solution is lyophilized until dry.
- the product shelf is cooled to 20° C. ⁇ 5° C.
- the lyophilized bulk drug product powder is milled.
- the milled powder is sieved.
- the sieved powder is blended for 30 minutes.
- a sterile tilter-set which consists of a 0.2 um polyvinylidene fluoride membrane filter (Durapore®, Millipore) and a 0.1 um polyvinylidene fluoride membrane filter (Durapore®, Millipore) connected in tandem. Confirm the integrity of each filter before and after the filtration. Take approximately 100 mL of the filtrate in order to check bioburden.
- a sterile filter-set which consists of a 0.2 um polyvinylidene fluoride membrane filter and a 0.1 um polyvinylidene fluoride membrane filter connected in tandem, and introduce the final filtrate into an aseptic room. Confirm the integrity of each filter before and after the filtration.
- Adjust the fill weight of the filtered compounded solution to 11.37 g (corresponds to 10 mL of the compounded solution), then start filling operation. Check the filled weight in sufficient frequency and confirm it is in target range (11.37 g ⁇ 1%, 11.26 to 11.43 g). When deviation from the control range (11.37 g ⁇ 2%, 11.14 to 11.59 g) is occurred, re-adjust the filling weight.
- Sodium Perchlorate Buffer Solution was made by dissolving 14.05 g of sodium perchlorate Monohydrate in 1000.0 mL of water followed by adjusting pH to 2.5 with diluted perchloric acid (1 in 20).
- Sodium Acetate Buffer Solution pH 5.5 (Diluent) was made by dissolving 1.36 g of sodium acetate trihydrate in 1000.0 mL of water followed by adjusting to pH 5.5 with diluted acetic acid (1 in 10).
- Sample solution dissolve 20.0 mg, exactly weighed, of Sample, in 20.0 mL of water (Prepare just before injection into HPLC system).
- System Suitability Solution (1%): take 1.0 mL of the Sample Solution (use first sample if more are present) and transfer into a 100.0 mL volumetric flask, dilute with water to volume and mix.
- a t area of CXA-101 peak in the sample chromatogram
- ⁇ A i total peak areas of impurities in the sample chromatogram
- the Amount of Sodium Chloride can be Selected to Stabilize Ceftolozane in Pharmaceutical Compositions
- the amount of sodium per mg of sodium chloride can be calculated (as known to one of ordinary skill in the art) based on the relative molar weight ratio of sodium and sodium chloride (e.g., 50 mg sodium chloride contains about 20 mg of sodium, etc).
- ceftolozane in ceftolozane sulfate can similarly be calculated based on the respective molecular molar weights of ceftolozane and ceftolozane sulfate (e.g., 1,147 mg ceftolozane sulfate contains about 1,000 mg of ceftolozane). Accordingly, a composition comprising about 1,147 mg ceftolozane sulfate and 480 mg of sodium chloride also contains 480 mg of sodium chloride per 1,000 mg of ceftolozane.
- FIG. 5A is Table 3 with data for total purity of ceftolozane measured by HPLC during the 7-day stability test using the HPLC method in Example 2, with the data plotted in the graph of FIG. 5B .
- FIG. 4 Stability data for amounts of additional substances in the ceftolozane compositions from Table 2 ( FIG. 4 ) as measured by peaks 1, 3 and 7 by HPLC (according to Example 2) are summarized in Tables 4-6, FIGS. 6A , 7 A and 8 A. The data are also plotted in FIGS. 6B , 7 B, and 8 B to show trends of total purity, peak 1, RRT 0.43+peak 3, and peak 7 with respect to sodium chloride (NaCl), respectively.
- FIG. 5A is Table 3 with total purity of ceftolozane measured by HPLC during the 7-day stability test, with the data plotted in the graph of FIG. 5B .
- the Amount of Sodium Chloride can be Selected to Stabilize Ceftolozane in Pharmaceutical Compositions Comprising Ceftolozane and Tazobactam
- a composition comprising ceftolozane, sodium chloride and tazobactam was prepared by co-lyophilizing a stabilizing amount of sodium chloride, ceftolozane sulfate and tazobactam acid in amounts described in Table 7 ( FIG. 9A ) together in an aqueous solution to obtain a stabilized ceftolozane lyophilized composition (“Co-Lyophilized Combo Drug Product”).
- the components of the composition that was lyophilized to obtain the Co-Lyophilized Combo Drug Product is shown in Table 7 ( FIG. 9A ).
- this composition included about 484 mg of sodium chloride per 1,000 mg ceftolozane active provided as ceftolozane sulfate, and a weight ratio of about 2:1 between the CXA101 and tazobactam acid.
- the Co-Lyophilized Combo Drug Product was characterized by amounts of the substances corresponding to HPLC peaks 1-12 that were less than the applicable drug product specification, indicating stabilization of the ceftolozane in the presence of about 484 mg of sodium chloride per 1,000 mg of ceftolozane active.
- a composition comprising ceftolozane, and a stabilizing amount of sodium chloride was lyophilized, and then blended with a separately lyophilized composition of tazobactam.
- the stabilized ceftolozane composition was formed by lyophilizing an aqueous solution of the “CXA-101 for Injection Bulk” row of Table 10 ( FIG. 10A ), which was then blended with 5.4 g tazobactam free acid to form a pharmaceutical composition containing ceftolozane, sodium chloride and tazobactam components (“Blend Combo Drug Product”).
- this composition included about 481 mg of sodium chloride per 1,000 mg ceftolozane active provided as ceftolozane sulfate, and a weight ratio of about 2:1 between the CXA101 and tazobactam acid.
- Blend Combo Drug Product was characterized by amounts of the substances corresponding to HPLC peaks 1-12 that were less than the applicable drug product specification, indicating stabilization of the ceftolozane in the presence of about 481 mg of sodium chloride per 1,000 mg of ceftolozane active.
- Example 3 A stability study was carried out at 60° c. as described in Example 3.
- the sodium chloride content in the CXA-201 compositions is described in Table 13, FIG. 11 .
- the HPLC data at 60° C. are summarized in Table 14-17, FIGS. 12-15 .
Abstract
Description
- This application claims priority to U.S. Provisional Patent Application No. 61/792,092, filed Mar. 15, 2013, and U.S. Provisional Patent Application No. 61/793,007, filed Mar. 15, 2013, both of which are incorporated herein in their entirety.
- This disclosure relates to pharmaceutical compositions comprising ceftolozane.
- Ceftolozane is a cephalosporin antibacterial agent, also referred to as CXA-101, FR264205, or by chemical names such as (6R,7R)-3-[(5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazol-2-ium-2-yl)methyl]-7-({(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, and 7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-{3-amino-4-[3-(2-aminoethyl)ureido]-2-methyl-1-pyrazolio}methyl-3-cephem-4-carboxylate.
- The prior art describes a variety of ceftolozane salts. For example, U.S. Pat. No. 7,129,232 discloses ceftolozane hydrogen sulfate salt among other salts “with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt [e.g., sodium salt, potassium salt, etc.], an alkaline earth metal salt [e.g., calcium salt, magnesium salt, etc.], an ammonium salt; a salt with an organic base, for example, an organic amine salt [e.g., trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N′-dibenzylethylenediamine salt, etc.]; an inorganic acid addition salt [e.g., hydrochloride, hydrobromide, sulfate, hydrogen sulfate, phosphate, etc.]; an organic carboxylic or sulfonic acid addition salt [e.g., formate, acetate, trifluoroacetate, maleate, tartrate, citrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.]; and a salt with a basic or acidic amino acid [e.g., arginine, aspartic acid, glutamic acid, etc.].” Ceftolozane sulfate is a pharmaceutically acceptable ceftolozane salt of formula (I) that can be formulated for intravenous administration or infusion.
- Certain pharmaceutical compositions containing ceftolozane are useful as antibiotics for the treatment of certain serious infections, including serious complicated intra-abdominal infections and complicated urinary tract infections. The ceftolozane pharmaceutical compositions can be administered as intravenous antibacterial agents to treat these infection. The antibacterial activity of ceftolozane is believed to result from its interaction with penicillin binding proteins (PBPs) to inhibit the biosynthesis of the bacterial cell wall which acts to stop bacterial replication. Antibacterial pharmaceutical compositions can include a therapeutically effective unit dose of a pharmaceutically acceptable salt of ceftolozane formulated for intravenous administration.
- As disclosed herein, ceftolozane was unstable in certain lyophilized pharmaceutical compositions initially evaluated for intravenous administration. In particular, a decrease in ceftolozane purity and the formation of multiple additional related substances were detected in certain initial ceftolozane pharmaceutical compositions by peaks in high purity liquid chromatography (HPLC) after stability testing. This testing pointed to the need to develop novel ceftolozane formulations providing increased ceftolozane stability. U.S. Pat. No. 7,129,232 discloses that “auxiliary substances” such as “stabilizing agents . . . and other commonly used additives” may be included in pharmaceutical compositions comprising ceftolozane or many other cephalosporin compounds “if needed.” However, the disclosure does not disclose a reduction in ceftolozane purity in pharmaceutical compositions containing ceftolozane sulfate, or the formation of additional related substances observed during stability testing. Nor does this disclosure provide guidance on the formation of ceftolozane pharmaceutical compositions to increase ceftolozane purity during stability testing or control the relative amounts of ceftolozane related substances detected by HPLC peak formation during stability testing.
- In view of the above, there is a need for pharmaceutical preparations containing ceftolozane compounds having improved ceftolozane stability.
- The pharmaceutical antibiotic compositions can include ceftolozane sulfate obtained by a process comprising the steps of lyophilizing an aqueous solution containing ceftolozane and a stabilizing amount of sodium chloride, where the stabilizing amount of sodium chloride is about 125 to 500 mg of sodium chloride (including, e.g., 480-500 mg) per 1,000 mg ceftolozane active in the aqueous solution prior to lyophilization. As disclosed in the Examples herein, high performance liquid chromatography (HPLC) analysis conducted during stability testing of lyophilized ceftolozane pharmaceutical compositions comprising between 50 and 481 mg sodium chloride and 1,000 mg of ceftolozane revealed an improved ceftolozane stability in compositions formed from aqueous solutions having at least 125 mg sodium chloride. Unexpectedly, lyophilized ceftolozane compositions having 125 mg or more sodium chloride relative to the fixed amount of ceftolozane active prior to lyophilization were about 35-90% more stable than comparable ceftolozane compositions having less than 125 mg sodium chloride, as measured by total ceftolozane purity during a 7-day stability study in Example 3. In addition, lyophilized ceftolozane compositions having 125 mg or more sodium chloride relative to the fixed amount of 1,000 mg ceftolozane active in an aqueous solution prior to lyophilization produced lyophilized compositions having lower quantities of additional substances identified by
peaks peaks - In particular, sodium chloride stabilized ceftolozane compositions described in Example 3 were characterized by about 37-94% less of the material of
peak 1 and about 38-306% less of the material of peak 7 (measured by corresponding HPLC peak areas) than comparable ceftolozane compositions having less than 125 mg sodium chloride (e.g., see 7-day stability study in Example 3). - The disclosed sodium chloride stabilized ceftolozane compositions can be characterized by decrease in ceftolozane total purity is not greater than 4.06% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250×4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH3CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C. These sodium chloride stabilized ceftolozane compositions were characterized by an increase in the amount of the impurity represented by Peak 1 not greater than 1.83% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250×4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH3CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C., where Peak 1 has a retention time relative to ceftolozane of 0.1.
- Accordingly, preferred pharmaceutical compositions contain ceftolozane sulfate having an improved stability as a decrease in the rate of ceftolozane purity and/or a decrease in the rate of formation of substances characterized by
HPLC peaks -
FIGS. 1A and 1B are chromatograms of CXA-101 ceftolozane drug substance obtained from the lyophilization process of Example 1. The chromatograms were obtained according to the analytical method described in Example 2. -
FIG. 2 is a diagram of a lyophilization process for the ceftolozane obtained according to the process described in Example 1. -
FIG. 3 is a table (Table 1) of peaks for the ceftolozane prepared by the lyophilization process in Example 1 obtained by HPLC according to the analytical method of Example 2. -
FIG. 4 is a table (Table 2) showing the composition of various additional ceftolozane pharmaceutical compositions in which the sodium chloride content is varied. -
FIG. 5A is a table (Table 3) showing the total purity of ceftolozane in the pharmaceutical compositions ofFIG. 4 , as measured by HPLC peak area according to the analytical method of described in Example 2. -
FIG. 5B is a graph showing the total purity of certain pharmaceutical compositions disclosed inFIG. 4 , as measured by HPLC peak area. -
FIG. 6A is a table (Table 4) showing the amount of material fromcharacteristic peak 1 in the pharmaceutical compositions ofFIG. 4 , as measured by HPLC peak area according to the analytical method of described in Example 2. -
FIG. 6B is a graph showing the amount of material fromcharacteristic peak 1 in the pharmaceutical compositions ofFIG. 4 , as measured by HPLC peak area according to the analytical method of described in Example 2. -
FIG. 7A is a table (Table 5) showing the amount of material fromcharacteristic peak 3 in the pharmaceutical compositions ofFIG. 4 , as measured by HPLC peak area according to the analytical method of described in Example 2. -
FIG. 7B is a graph showing the amount of material fromcharacteristic peak 3 in the pharmaceutical compositions ofFIG. 4 , as measured by HPLC peak area according to the analytical method of described in Example 2. -
FIG. 8A is a table (Table 6) showing the amount of material fromcharacteristic peak 7 in the pharmaceutical compositions ofFIG. 4 , as measured by HPLC peak area according to the analytical method of described in Example 2. -
FIG. 8B is a graph showing the amount of material fromcharacteristic peak 7 in the pharmaceutical compositions ofFIG. 4 , as measured by HPLC peak area according to the analytical method of described in Example 2. -
FIG. 9A is a table (Table 7) showing the formulation composition of the Co-Lyo-Combo Drug Product used in Example 4A. -
FIG. 9B is a table (Table 8) showing impurity concentrations at time zero, one month and three months at 25° C./60% relative humidity of the Co-Lyo-Combo Drug Product. -
FIG. 9C is a table (Table 9) showing impurity concentrations at time zero, one month and three months at 40° C./75% relative humidity of the Co-Lyo-Combo Drug Product. -
FIG. 10A is a table (Table 10) showing the formulation composition of the Blend Drug Product used in Example 4B. -
FIG. 10B is a table (Table 11) showing impurity concentrations at time zero, one month and three months at 25° C./60% relative humidity of the Blend Drug Product used in Example 4B. -
FIG. 10C is a table (Table 12) showing impurity concentrations at time zero, one month and three months at 40° C./75% relative humidity of the Blend Drug Product used in Example 4B. -
FIG. 11 is a table (Table 13) showing the composition of various ceftolozane pharmaceutical compositions in which the sodium chloride concentration is varied. -
FIG. 12 is a table (Table 14) showing the purity of Ceftolozane in CXA-201 Compositions with varying amounts of sodium from sodium chloride at time zero, 1 day, 3 days and 7 days at at 30° C. and 60° C. -
FIG. 13 is a table (Table 15) showing the HPLC area of Impurity ofPeak 1 in CXA-201 Compositions with varying amounts of sodium from sodium chloride at time zero, 1 day, 3 days and 7 days at 30° C. and at 60° C. -
FIG. 14 is a table (Table 16) showing the HPLC area of the Impurity at RRT 0.43 andImpurity Peak 3 in CXA-201 Compositions with varying amounts of sodium from sodium chloride at time zero, 1 day, 3 days and 7 days at 30° C. and at 60° C. -
FIG. 15 is a table (Table 17) showing the HPLC area of Impurity ofPeak 7 in CXA-201 Compositions with varying amounts of sodium from sodium chloride at time zero, 1 day, 3 days and 7 days at 30° C. and at 60° C. -
FIG. 16 is a table (Table 18) showing the finished drug product unit composition of ceftolozane/tazolactam. -
FIG. 17 is a table (Table 19) showing the primary container closure system for the ceftolozane/tazobactam unit product. - Ceftolozane sulfate can be stabilized in lyophilized pharmaceutical compositions by incorporation of a stabilizing-effective amount of an inorganic salt stabilizing agent in a solution that can be lyophilized to obtain a lyophilized composition containing stabilized ceftolozane. The stabilizing-effective amount of a sodium chloride inorganic salt stabilizing agent is preferably 125 mg to 500 mg (preferably about 480-500 mg) of sodium chloride per 1,000 mg of ceftolozane active.
- In particular, pharmaceutical compositions comprising ceftolozane and stabilizing amount of sodium chloride can be obtained by lyophilization of a solution comprising a stabilizing-effective amount of sodium chloride and ceftolozane sulfate. Alternatively, they can be obtained by other methods. As is known to those skilled in the art, lyophilization is a process of freeze-drying in which water is sublimed from a frozen solution of one or more solutes. Specific methods of lyophilization are described in Remington's Pharmaceutical Sciences, Chapter 84, page 1565, Eighteenth Edition, A. R. Gennaro, (Mack Publishing Co., Easton, Pa., 1990). A pharmaceutical composition comprising ceftolozane can be prepared by adding a stabilizing amount of sodium chloride in a fixed ratio to ceftolozane in an aqueous solution prior to lyophilization, then lyophilizing the solution to obtain a lyophilized composition comprising sodium chloride and ceftolozane.
- In particular, the pharmaceutical antibiotic compositions can include ceftolozane sulfate obtained by a process comprising the steps of lyophilizing an aqueous solution containing ceftolozane and a stabilizing amount of sodium chloride, where the stabilizing amount of sodium chloride is about 125 to 500 mg (preferably, 480-500 mg) of sodium chloride per 500 mg ceftolozane active in the aqueous solution prior to lyophilization. The pharmaceutical compositions comprising ceftolozane disclosed herein can be prepared by adding 125 to 500 mg (preferably, 480-500 mg) sodium chloride per 1000 mg of ceftolozane prior to lyophilization (or spray drying). For example, the pharmaceutical compositions can be obtained by a method comprising the steps of adding a stabilizing amount (e.g., 125 to 500 mg [more preferably, 480-500 mg] sodium chloride per 1000 mg of ceftolozane active) followed by lyophilizing (or spray drying) the composition comprising the sodium chloride and ceftolozane. In one aspect (e.g., Example 1), ceftolozane and a stabilizing amount of sodium chloride can be dissolved in an aqueous solution that can be lyophilized (or spray drying) to obtain a ceftolozane pharmaceutical composition.
- The pharmaceutical compositions may comprise other additional components including stabilizers, pH adjusting additives (e.g., buffers) and the like. Non-limiting examples of these additives include sodium chloride, citric acid and L-arginine. For example, the pharmaceutical antibiotic compositions can include ceftolozane sulfate obtained by a process comprising the steps of lyophilizing an aqueous solution containing ceftolozane sulfate with a stabilizing amount of sodium chloride (e.g., 125 to 500 mg [more preferably, 480-500 mg] of sodium chloride per 1,000 mg ceftolozane active), with L-arginine and/or citric acid in the aqueous solution prior to lyophilization. The use of sodium chloride results in greater ceftolozane stability, while an amount of L-arginine can be used that is effective to adjust pH and to increase the solubility of ceftolozane, and citric acid can be included in an amount effective to reduce or prevent discoloration of the product, due to its ability to chelate metal ions. The aqueous solution can be subsequently lyophilized (or spray dried) to obtain a stabilized lyophilized ceftolozane sulfate composition comprising ceftolozane sulfate, sodium chloride, L-arginine and citric acid.
- The pharmaceutical composition can also be a Ceftolozane/Tazobactam for Injection Drug Product, 1000 mg/500 mg. It is presented as a combination of two sterile active powders in a single vial intended for reconstitution and intravenous infusion.
- The drug product is first prepared by converting ceftolozane sulfate drug substance to a sterile drug product intermediate (DPI) powder with excipients citric acid, sodium chloride and L-arginine. This is commonly done by lyophilization, as described above. Tazobactam sodium drug substance is presented as a sterile powder without any excipients. The tazobactam sodium drug substance is typically lyophilized (or spray dried). The drug product is then prepared by aseptically filling the two powders (e.g., the two separately lyophilized drug powders or spray dried powders) sequentially into a single vial.
- Each vial of ceftolozane/tazobactam for injection contains approximately 2255 mg ceftolozane sterile DPI powder that contains 1147 mg ceftolozane sulfate, which is equivalent to 1000 mg ceftolozane free base, as well as approximately 537 mg tazobactam sodium sterile drug substance, equivalent to 500 mg tazobactam free acid. At the time of administration, the vial is reconstituted with 10 mL vehicle, 5% Dextrose Injection USP, sterile Water for Injection or 0.9% Sodium Chloride Injection USP, then the vial contents further diluted in an infusion bag of 0.9% Sodium Chloride Injection USP or 5% Dextrose Injection USP, for administration. The constituents are shown in Table 18,
FIG. 16 . - The primary container-closure system is a
Type 1 20 mL molded glass vial with 20 mm neck finish. The vial is sealed by a 20 mm rubber stopper and 20 mm plastic flip-cap seal with aluminum ferrule. The primary contain-closure system used for the ceftolozane/tazobactam unit product is summarized in Table 19,FIG. 17 . - In other embodiments, pharmaceutical compositions comprising ceftolozane can be obtained by methods that include the steps of: (1) adding a stabilizing amount of sodium chloride to ceftolozane (or preparing an aqueous solution of sodium chloride and ceftolozane) optionally followed by co-lyophilizing or spray drying the ceftolozane and sodium chloride (or aqueous solution thereof); and (2) combining the product of step (1) with other components. For example, the product of step (1) can be combined with a β-lactamase inhibitor, such as tazobactam (CAS#: 89786-04-9), avibactam (CAS#1192500-31-4), Sulbactam (CAS#68373-14-8) and/or clavulanate (CAS#58001-44-8). The beta lactamase inhibitor can be included in a crystalline or amorpous form, such as a lyophilized tazobactam or crystalline tazobactam (e.g., U.S. Pat. Nos. 8,476,425 and 5,763,603) to obtain the pharmaceutical composition.
- The stabilizing effect of sodium chloride on ceftolozane can be measured by high performance liquid chromatography (HPLC) analysis, for example by detecting the ratio of peak areas obtained for ceftolozane compared to peaks for other substances. Various ceftolozane compositions having 50-481 mg of sodium chloride per 1,000 mg ceftolozane active as described in Table 2 (
FIG. 4 ) were tested for stability as described in Example 3. The stability testing of lyophilized ceftolozane pharmaceutical compositions (Example 3) revealed improved ceftolozane stability in compositions formed from aqueous solutions having at least 125 mg sodium chloride. Unless otherwise indicated, HPLC measurements reported herein are obtained using a Develosil column ODS-UG-5; 5 micrometers; 250×4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH3CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C. - Unexpectedly, lyophilized ceftolozane compositions having 125 mg more sodium chloride relative to the fixed amount of ceftolozane prior to lyophilization were about 35-90% more stable than comparable ceftolozane compositions having less than 125 mg sodium chloride, as measured by total ceftolozane purity during a 7-day stability study in Example 3. Referring to the data in Table 3 (
FIGS. 5A and 5B ), the total purity of ceftolozane (measured by HPLC according to Example 2) was measured by the % decrease in the ceftolozane HPLC peak during the 7-day stability test. In particular, samples obtained by lyophilizing compositions containing 125 mg, 190 mg and 481 mg of sodium chloride per 1,000 mg of ceftolozane active showed a decrease in ceftolozane that was at least about 35% less than reductions in ceftolozane observed for formulations containing 50 mg or 75 mg sodium chloride per 1,000 mg ceftolozane active (e.g., the % decrease in ceftolozane for the sample containing 75 mg sodium chloride was about 35% greater than the comparable % decrease in ceftolozane for the sample containing 190 mg sodium chloride). In addition, samples obtained by lyophilizing compositions containing 125 mg, 190 mg and 481 mg of sodium chloride per 1,000 mg of ceftolozane active showed a decrease in ceftolozane that was up to about 90% less than reductions in ceftolozane observed for forulations containing 50 mg or 75 mg sodium chloride per (e.g., the % decrease in ceftolozane for the sample containing 50 mg sodium chloride was about 90% greater than the comparable % decrease in ceftolozane for the sample containing 481 mg sodium chloride). - In addition, lyophilized ceftolozane compositions having 125 mg more sodium chloride relative to the fixed amount of 1,000 mg ceftolozane active in an aqueous solution prior to lyophilization produced lyophilized compositions having lower quantities of additional substances identified by
peaks FIG. 3 , indicating retention times of about 0.1 forpeak 1 and about 1.3 forpeak 7 relative to celftolozane measured according to the HPLC method of Example 2). In particular, these sodium chloride stabilized ceftolozane compositions were characterized by about 37-94% less of the material ofpeak 1 and about 38-306% less of the material of peak 7 (measured by corresponding HPLC peak areas) than comparable ceftolozane compositions having less than 125 mg sodium chloride (e.g., see 7-day stability study in Example 3). - Referring to the data in Table 4 (
FIGS. 6A and 6B ), the amount of the composition of peak 1 (measured by HPLC according to Example 2) was measured by the % increase in thepeak 1 HPLC peak during the 7-day stability test of Example 3. In particular, samples obtained by lyophilizing compositions containing 125 mg, 190 mg and 481 mg of sodium chloride per 1,000 mg of ceftolozane active showed at least a 37% reduction in the amount of thepeak 1 composition observed for these formulations containing at least 125 mg sodium chloride per 1,000 mg ceftolozane active, compared to the compositions obtained by lyophilizing 50 mg or 75 mg sodium chloride per 1,000 mg of ceftolozane active (e.g., the % increase inpeak 1 for the sample containing 75 mg sodium chloride was about 37% greater than the comparable % decrease in ceftolozane for the sample containing 190 mg sodium chloride). In addition, samples obtained by lyophilizing compositions containing 125 mg, 190 mg and 481 mg of sodium chloride per 1,000 mg of ceftolozane active showed up to a 94% reduction in the amount of thepeak 1 composition observed for these formulations containing at least 125 mg sodium chloride per 1,000 mg ceftolozane active, compared to the compositions obtained by lyophilizing 50 mg or 75 mg sodium chloride per 1,000 mg of ceftolozane active (e.g., the % increase inpeak 1 for the sample containing 50 mg sodium chloride was about 94% greater than the comparable % decrease in ceftolozane for the sample containing 481 mg sodium chloride). - Referring to the data in Table 5 (
FIGS. 7A and 7B ), the amount of the composition of peak 3 (measured by HPLC according to Example 2) was measured by the % increase in thepeak 1 HPLC peak during the 7-day stability test of Example 3. In particular, samples obtained by lyophilizing compositions containing 125 mg and 190 mg of sodium chloride per 1,000 mg of ceftolozane active showed at least a 269% reduction in the amount of thepeak 3 composition observed for these formulations containing at least 125 mg sodium chloride per 1,000 mg ceftolozane active, compared to the compositions obtained by lyophilizing 50 mg or 75 mg sodium chloride per 1,000 mg of ceftolozane active (e.g., the % increase inpeak 3 for the sample containing 50 mg sodium chloride was about 269% greater than the comparable % decrease in ceftolozane for the sample containing 190 mg sodium chloride). In addition, samples obtained by lyophilizing compositions containing 125 mg or 190 mg of sodium chloride per 1,000 mg of ceftolozane active showed up to a 333% reduction in the amount of thepeak 3 composition observed for these formulations containing at least 125 mg sodium chloride per 1,000 mg ceftolozane active, compared to the compositions obtained by lyophilizing 50 mg or 75 mg sodium chloride per 1,000 mg of ceftolozane active (e.g., the % increase inpeak 3 for the sample containing 75 mg sodium chloride was about 333% greater than the comparable % decrease in ceftolozane for the sample containing 125 mg sodium chloride). The ceftolozane sample containing 481 mg of sodium chloride had a higher amount of the composition ofpeak 3 than the ceftolozane samples containing 50 mg or 75 mg of sodium chloride. - Referring to the data in Table 6 (
FIGS. 8A and 8B ), the amount of the composition of peak 7 (measured by HPLC according to Example 2) was measured by the % increase in thepeak 7 HPLC peak during the 7-day stability test of Example 3. In particular, samples obtained by lyophilizing compositions containing 125 mg, 190 mg and 481 mg of sodium chloride per 1,000 mg of ceftolozane active showed at least a 38% reduction in the amount of thepeak 7 composition observed for these formulations containing at least 125 mg sodium chloride per 1,000 mg ceftolozane active, compared to the compositions obtained by lyophilizing 50 mg or 75 mg sodium chloride per 1,000 mg of ceftolozane active (e.g., the % increase inpeak 7 for the sample containing 75 mg sodium chloride was about 38% greater than the comparable % decrease in ceftolozane for the sample containing 125 mg sodium chloride). In addition, samples obtained by lyophilizing compositions containing 125 mg, 190 mg and 481 mg of sodium chloride per 1,000 mg of ceftolozane active showed up to a 306% reduction in the amount of thepeak 7 composition observed for these formulations containing at least 125 mg sodium chloride per 1,000 mg ceftolozane active, compared to the compositions obtained by lyophilizing 50 mg or 75 mg sodium chloride per 1,000 mg of ceftolozane active (e.g., the % increase inpeak 7 for the sample containing 50 mg sodium chloride was about 306% greater than the comparable % decrease in ceftolozane for the sample containing 481 mg sodium chloride). - Accordingly, preferred pharmaceutical compositions contain ceftolozane sulfate having an improved stability as a decrease in the rate of ceftolozane purity and/or a decrease in the rate of formation of substances characterized by
HPLC peaks FIG. 5A ) and chemical stability (e.g., with respect to the composition ofHPLC peak 1 in Table 4,FIG. 6A ) compared pharmaceutical compositions comprising ceftolozane with comparatively less sodium chloride. - Pharmaceutical compositions comprising ceftolozane can be formulated to treat infections by parenteral administration (including subcutaneous, intramuscular, and intravenous) administration. Pharmaceutical compositions may additionally comprise excipients, stabilizers, pH adjusting additives (e.g., buffers) and the like. Non-limiting examples of these additives include sodium chloride, citric acid and L-arginine. For example, the use of sodium chloride results in greater stability; L-arginine is used to adjust pH and to increase the solubility of ceftolozane; and citric acid is used to prevent discoloration of the product, due to its ability to chelate metal ions. In one particular embodiment, the pharmaceutical compositions described herein are formulated for administration by intravenous injection or infusion. Pharmaceutical antibiotic compositions can include ceftolozane sulfate and stabilizing amount of sodium chloride (e.g., 125 to 500 mg of sodium chloride per 1,000 mg ceftolozane active) in a lyophilized unit dosage form (e.g., powder in a vial). The unit dosage form can be dissolved with a pharmaceutically acceptable carrier, and then intravenously administered. In another aspect, pharmaceutical antibiotic compositions can include ceftolozane sulfate obtained by a process comprising the steps of lyophilizing an aqueous solution containing ceftolozane and a stabilizing amount of sodium chloride, where the stabilizing amount of sodium chloride is about 125 to 500 mg of sodium chloride per 1,000 mg ceftolozane active in the aqueous solution prior to lyophilization.
- In one aspect, provided herein is a method for the treatment of bacterial infections in a mammal, comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition prepared according to the methods described herein. A method for the treatment of bacterial infections in a mammal can comprise administering to said mammal a therapeutically effective amount of a pharmaceutical composition comprising ceftolozane sulfate and sodium chloride. Non-limiting examples of bacterial infections that can be treated by the methods of the invention include infections caused by: aerobic and facultative gram-positive microorganisms (e.g., Staphylococcus aureus, Enterococcus faecalis, Staphylococcus epidermidis, Streptococcus agalactiae, Streptococcus pneumonia, Streptococcus pyogenes, Viridans group streptococci), aerobic and facultative gram-negative microorganisms (e.g., Acinetobacter baumanii, Escherichia coli, Haemophilus influenza, Klebsiella pneumonia, Pseudomonas aeruginosa, Citrobacter koseri, Moraxella catarrhalis, Morganella morganii, Neisseria gonorrhoeae, Proteus mirabilis, Proteus vulgaris, Serratia marcescens, Providencia stuartii, Providencia rettgeri, Salmonella enterica), gram-positive anaerobes (Clostridium perfringens), and gram-negative anaerobes (e.g., Bacteroides fragilis group (e.g., B. fragilis, B. ovatus, B. thetaiotaomicron, and B. vulgates), Bacteroides distasonis, Prevotella melaminogenica). In certain embodiments of the methods described herein, bacterial infection is associated with one or more of the following conditions: complicated intra-abdominal infections, complicated urinary tract infections (cUTIs) and pneumonia (e.g., community-acquired, or nosocomial pneumonia). Community-acquired pneumonia (moderate severity only) can include infections caused by piperacillin-resistant, beta-lactamase producing strains of Haemophilus influenza. Nosocomial pneumonia (moderate to severe) caused by piperacillin-resistant, beta-lactamase producing strains of Staphylococcus aureus and by Acinetobacter baumanii, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
- As used herein, “treating”, “treat” or “treatment” describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of a pharmaceutical composition of the present invention to alleviate the symptoms or complications of a disease, condition or disorder, or to reduce the extent of the disease, condition or disorder. The term “treat” can also include treatment of a cell in vitro or an animal model.
- By a “therapeutically effective amount” of a compound of the invention is meant a sufficient amount of the compound to treat the disorder (e.g., bacterial infection). The specific therapeutically effective amount that is required for the treatment of any particular patient or organism (e.g., a mammal) will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound or composition employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts (see, for example, Goodman and Gilman's, “The Pharmacological Basis of Therapeutics”, Tenth Edition, A. Gilman, J. Hardman and L. Limbird, eds., McGraw-Hill Press, 155-173, 2001, which is incorporated herein by reference in its entirety). The therapeutically effective amount for a given situation can be readily determined by routine experimentation and is within the skill and judgment of the ordinary clinician.
- As used herein, “125-500 mg sodium chloride per 1000 mg of ceftolozane” refers to a ratio of sodium chloride to ceftolozane active. The phrase “125-500 mg sodium chloride per 1000 mg of ceftolozane” includes “62.5 to 250 mg sodium chloride per 500 mg of ceftolozane active” and other similar weight ratios. In addition, “1,000 mg of ceftolozane as ceftolozane sulfate” refers to an amount of ceftolozane sulfate effective to provide 1,000 mg of ceftolozane. The amount of sodium per gram of ceftolozane activity in a pharmaceutical composition containing ceftolozane sulfate and sodium chloride can be calculated using the relevant molecular weights of ceftolozane, ceftolozane sulfate, sodium chloride and sodium.
- As used herein, “1000 mg ceftolozane” refers to an amount of ceftolozane that is considered a bioequivalent by the United States Food and Drug Administration (FDA), i.e. for which 90% CI of the relative mean Cmax, AUC(0-t) and AUC(0-∞) is within 80.00% to 125.00% of the reference formulation in the fasting state (see: “Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations”. Center for Drug Evaluation and Research, United States Food and Drug Administration, 2003).
- “Ceftolozane active” refers to the active portion of a salt form of ceftolozane, i.e., the free base form of ceftolozane.
- In another aspect, the disclosed sodium chloride stabilized ceftolozane compositions can be characterized by decrease in ceftolozane total purity is not greater than 3.7% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250×4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH3CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C. In another aspect, the disclosed sodium chloride stabilized ceftolozane compositions can be characterized by decrease in ceftolozane total purity is not greater than 4.2% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250×4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH3CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C. In another aspect, the disclosed sodium chloride stabilized ceftolozane compositions can be characterized by decrease in ceftolozane total purity is not greater than 4.5% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250×4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH3CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C. In another aspect, the disclosed sodium chloride stabilized ceftolozane compositions can be characterized by decrease in ceftolozane total purity is not greater than 5.0% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250×4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH3CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C.
- In another aspect, the disclosed sodium chloride stabilized ceftolozane compositions were characterized by an increase in the amount of the impurity represented by
Peak 1 not greater than 1.8% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250×4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH3CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C., wherePeak 1 has a retention time relative to ceftolozane of 0.1. In another aspect, the disclosed sodium chloride stabilized ceftolozane compositions were characterized by an increase in the amount of the impurity represented byPeak 1 not greater than 2.0% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250×4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH3CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C., wherePeak 1 has a retention time relative to ceftolozane of 0.1. In another aspect, the disclosed sodium chloride stabilized ceftolozane compositions were characterized by an increase in the amount of the impurity represented byPeak 1 not greater than 2.2% after storing the pharmaceutical composition for seven days at 60° C., as determined by HPLC using a Develosil column ODS-UG-5; 5 micrometers; 250×4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH3CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C., wherePeak 1 has a retention time relative to ceftolozane of 0.1. - There are four main steps in the manufacture of CXA-101 bulk drug product: dissolution, sterile filtration, bulk lyophilization, and packaging into Sterbags®. These four main steps are composed of a total of 20 minor steps. The CXA-101 bulk drug product manufacturing process is presented below.
- 1. The prescribed amount of water for injection (“WFI”) is charged into the dissolution reactor.
- 2. A prescribed amount of citric acid is added.
- 3. The solution is cooled at 5° C. to 10° C.
- 4. A prescribed amount of CXA-101 drug substance is added to the solution.
- 5. A prescribed amount of L-arginine is slowly added to the solution.
- 6. A check for complete dissolution is performed. Solution pH is verified to be in the target range of 6.5 to 7.0.
- 7. A prescribed amount of sodium chloride is added to the solution, wherein the preferred amount of sodium chloride is 125-500 mg of sodium chloride per 1000 mg of ceftolozane active.
- 8. A check for complete dissolution is performed. Solution pH is verified to be in the target range of 6.0 to 7.0. If the pH is out of this range adjust with either L-Arginine or citric acid.
- 9. WFI is added to bring the net weight to 124.4 kg and the solution is mixed well.
- 10. Samples are withdrawn for testing of final pH.
- 11. The solution is passed through the filter (pore size 0.45 μm) followed by double filters (pore size 0.22 μm) onto a shelf on the Criofarma lyophilizer.
- 12. The line is washed with WFI.
- 13. The washing solution is passed from
Step 12 through sterile filtration. - 14. The washing solution is loaded onto a separate shelf in the lyophilizer (and later discarded).
- 15. The solution is lyophilized until dry.
- 16. The product shelf is cooled to 20° C.±5° C.
- IV. Packaging into Sterbags®
- 17. The lyophilized bulk drug product powder is milled.
- 18. The milled powder is sieved.
- 19. The sieved powder is blended for 30 minutes.
- 20. The powder is then discharged into Sterbags®
- Filtrate the compounded solution with a sterile tilter-set which consists of a 0.2 um polyvinylidene fluoride membrane filter (Durapore®, Millipore) and a 0.1 um polyvinylidene fluoride membrane filter (Durapore®, Millipore) connected in tandem. Confirm the integrity of each filter before and after the filtration. Take approximately 100 mL of the filtrate in order to check bioburden.
- Filter the prefiltered compounded solution through a sterile filter-set which consists of a 0.2 um polyvinylidene fluoride membrane filter and a 0.1 um polyvinylidene fluoride membrane filter connected in tandem, and introduce the final filtrate into an aseptic room. Confirm the integrity of each filter before and after the filtration.
- Wash a sufficient quantity of 28 mL vials with water for injection and sterilize the washed vials by a dry-heat sterilizer. Then transfer the sterilized vials into a Grade A area located in an aseptic room.
- Wash a sufficient quantity of stoppers with, water for injection. Sterilize and dry the washed stoppers by steam sterilizer. Then transfer the sterilized stoppers into a Grade A area located in an aseptic room.
- Sterilize a sufficient quantity of flip-off caps by steam sterilizer. Then transfer the sterilized flip-off caps into a Grade A or B area located in an aseptic room.
- Adjust the fill weight of the filtered compounded solution to 11.37 g (corresponds to 10 mL of the compounded solution), then start filling operation. Check the filled weight in sufficient frequency and confirm it is in target range (11.37 g±1%, 11.26 to 11.43 g). When deviation from the control range (11.37 g±2%, 11.14 to 11.59 g) is occurred, re-adjust the filling weight.
- Immediately after a vial is filled, partially stopper the vial with a sterilized stopper. Load the filled and partially stoppered vials onto the shelves of a lyophilizer aseptically.
- After all filled and partially stoppered vials are loaded into a lyophilizer, start the lyophilization program shown in
FIG. 2 . Freeze the loaded vials at −40° C. and keep until all vials freeze. Forward the program to primary drying step (shelf temperature; −20° C., chamber pressure; 100 to 150 mTorr). Primary drying time should be determined by monitoring the product temperature. Forward the program to secondary drying step (shelf temperature; 30° C., chamber pressure; not more than 10 mTorr) after completion of the primary drying step. After all vials are dried completely, return the chamber pressure to atmospheric pressure with sterilized nitrogen. Then stopper vials completely. - Unload the lyophilized vials from the chamber and crimp with sterilized flip-off caps.
- Subject all crimped vials to visual inspection and label and package all passed vials.
-
-
Column Develosil ODS-UG-5; 5 μm, 250 × 4.6 mm (Nomura Chemical, Japan) Mobile phase Sodium Perchlorate Buffer Solution (PH 2.5)/CH3CN 90:10 (vlv) Flow rate 1.0 mL/min Wavelength 254 nm Injection volume 10 μL Oven Temperature 45° C. Run Time 85 minutes -
-
Time (min) A % B % 0 75 25 30 70 30 60 0 100 85 0 100 85.1 75 25 110 75 25 - Sodium Perchlorate Buffer Solution was made by dissolving 14.05 g of sodium perchlorate Monohydrate in 1000.0 mL of water followed by adjusting pH to 2.5 with diluted perchloric acid (1 in 20).
- Mobile Phase was then made by mixing Sodium Perchlorate Buffer Solution (pH 2.5) and acetonitrile in the ratio 90:10 (v/v).
- Sodium Acetate Buffer Solution pH 5.5 (Diluent) was made by dissolving 1.36 g of sodium acetate trihydrate in 1000.0 mL of water followed by adjusting to pH 5.5 with diluted acetic acid (1 in 10).
- Sample solution: dissolve 20.0 mg, exactly weighed, of Sample, in 20.0 mL of water (Prepare just before injection into HPLC system).
- System Suitability Solution (1%): take 1.0 mL of the Sample Solution (use first sample if more are present) and transfer into a 100.0 mL volumetric flask, dilute with water to volume and mix.
- 1. Inject Blank (water)
2. Inject System Suitability Solution and check for tailing factor and theoretical plate number for CXA-101 peak: -
- The tailing factor must not be greater than 1.5
- Theoretical plates number must not be less than 10000
- 4. Inject System Suitability Solution and check for tailing factor and theoretical plate number for CXA-101 peak.
-
- The tailing factor must not be greater than 1.5
- Theoretical plates number must not be less than 10000
5. Identify the peaks of Related Substances in the Sample chromatogram based on the reference chromatogram reported inFIGS. 1A and 1B or, alternatively, on the basis of the RRT values reported in Table 1 (FIG. 3 ), with a retention time of about 0.14 relative to ceftolozane is believed to have the chemical structure of formula (II):
- I. Report for each related substance its amount as expressed by area percent.
-
- wherein:
- Ci=Amount of related substance i in the Sample, area %
- Ai=Peak area of related substance i in the Sample chromatogram
- At=Area of CXA-101 peak in the Sample chromatogram
- At+Σ Ai=Total peaks area in the Sample chromatogram
- Consider as any Unspecified Impurity, each peak in the chromatogram except CXA-101, peaks from 1 to 11 and every peak present in the blank chromatogram and report the largest.
- II. Report the total impurities content as expressed by the following formula:
-
- wherein:
- CT=total impurities content in the Sample, area %
- At=area of CXA-101 peak in the sample chromatogram
- Σ Ai=total peak areas of impurities in the sample chromatogram
- Multiple stability studies were performed on ceftolozane sulfate, wherein the effect of varying amounts of sodium chloride on the stability of ceftolozane was examined.
- The amount of sodium per mg of sodium chloride can be calculated (as known to one of ordinary skill in the art) based on the relative molar weight ratio of sodium and sodium chloride (e.g., 50 mg sodium chloride contains about 20 mg of sodium, etc).
- The amount of ceftolozane in ceftolozane sulfate can similarly be calculated based on the respective molecular molar weights of ceftolozane and ceftolozane sulfate (e.g., 1,147 mg ceftolozane sulfate contains about 1,000 mg of ceftolozane). Accordingly, a composition comprising about 1,147 mg ceftolozane sulfate and 480 mg of sodium chloride also contains 480 mg of sodium chloride per 1,000 mg of ceftolozane.
- A. CXA-101 Purity Increases in Compositions Having at Least about 125 Mg NaCl/1,000 Mg Ceftolozane Active
- A stability study was carried out at 60° C. as described herein. Sodium chloride content in test samples is described in Table 2 (
FIG. 4 ). The samples were formulated with 481, 190, 125, 75, and 50 mg sodium chloride per 1 g of ceftolozane active. -
FIG. 5A is Table 3 with data for total purity of ceftolozane measured by HPLC during the 7-day stability test using the HPLC method in Example 2, with the data plotted in the graph ofFIG. 5B . - B. The Amount of Substances Identified by
HPLC Peaks - A stability study was carried out at and 60° C. as described herein. Sodium chloride content in test samples is described in Table 2 (
FIG. 4 ). The samples were formulated with 481, 190, 125, 75, and 50 mg sodium chloride per 1 g of ceftolozane active. - Stability data for amounts of additional substances in the ceftolozane compositions from Table 2 (
FIG. 4 ) as measured bypeaks FIGS. 6A , 7A and 8A. The data are also plotted inFIGS. 6B , 7B, and 8B to show trends of total purity,peak 1, RRT 0.43+peak 3, andpeak 7 with respect to sodium chloride (NaCl), respectively.FIG. 5A is Table 3 with total purity of ceftolozane measured by HPLC during the 7-day stability test, with the data plotted in the graph ofFIG. 5B . - A. Stabilized Ceftolozane Compositions Co-Lyophilized with Tazobactam
- A composition comprising ceftolozane, sodium chloride and tazobactam was prepared by co-lyophilizing a stabilizing amount of sodium chloride, ceftolozane sulfate and tazobactam acid in amounts described in Table 7 (
FIG. 9A ) together in an aqueous solution to obtain a stabilized ceftolozane lyophilized composition (“Co-Lyophilized Combo Drug Product”). The components of the composition that was lyophilized to obtain the Co-Lyophilized Combo Drug Product is shown in Table 7 (FIG. 9A ). Notably, this composition included about 484 mg of sodium chloride per 1,000 mg ceftolozane active provided as ceftolozane sulfate, and a weight ratio of about 2:1 between the CXA101 and tazobactam acid. - The results of a stability study of the Co-Lyophilized Combo Drug Product are shown in Table 8 (
FIG. 9B ) and Table 9 (FIG. 9C ) as representative examples that summarize the results at 25° C./RH=60% and 40° C./RH=75% after one month (T1) and three months (T2). Samples were analyzed using a HPLC method as described in Example 2. - Referring to the data in Tables 8 and 9, the Co-Lyophilized Combo Drug Product was characterized by amounts of the substances corresponding to HPLC peaks 1-12 that were less than the applicable drug product specification, indicating stabilization of the ceftolozane in the presence of about 484 mg of sodium chloride per 1,000 mg of ceftolozane active.
- B. Stabilized Ceftolozane Compositions Lyophilized without Tazobactam
- A composition comprising ceftolozane, and a stabilizing amount of sodium chloride was lyophilized, and then blended with a separately lyophilized composition of tazobactam. The stabilized ceftolozane composition was formed by lyophilizing an aqueous solution of the “CXA-101 for Injection Bulk” row of Table 10 (
FIG. 10A ), which was then blended with 5.4 g tazobactam free acid to form a pharmaceutical composition containing ceftolozane, sodium chloride and tazobactam components (“Blend Combo Drug Product”). Notably, this composition included about 481 mg of sodium chloride per 1,000 mg ceftolozane active provided as ceftolozane sulfate, and a weight ratio of about 2:1 between the CXA101 and tazobactam acid. - The results of a stability study of the Blend Combo Drug Product are shown in Table 11 (
FIG. 10B ) and Table 12 (FIG. 10C ) as representative examples that summarize the results at 25° C./RH=60% and 40° C./RH=75% after one month (T1) and three months (T2). Samples were analyzed using a HPLC method as described in Example 2. - Referring to the data in tables 11 and 12, the Blend Combo Drug Product was characterized by amounts of the substances corresponding to HPLC peaks 1-12 that were less than the applicable drug product specification, indicating stabilization of the ceftolozane in the presence of about 481 mg of sodium chloride per 1,000 mg of ceftolozane active.
- A stability study was carried out at 60° c. as described in Example 3. The sodium chloride content in the CXA-201 compositions is described in Table 13,
FIG. 11 . The HPLC data at 60° C. are summarized in Table 14-17,FIGS. 12-15 .
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/212,781 US20140274990A1 (en) | 2013-03-15 | 2014-03-14 | Ceftolozane pharmaceutical compositions |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361793007P | 2013-03-15 | 2013-03-15 | |
US201361792092P | 2013-03-15 | 2013-03-15 | |
US14/212,781 US20140274990A1 (en) | 2013-03-15 | 2014-03-14 | Ceftolozane pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140274990A1 true US20140274990A1 (en) | 2014-09-18 |
Family
ID=51522651
Family Applications (12)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/213,532 Abandoned US20140274991A1 (en) | 2013-03-15 | 2014-03-14 | Ceftolozane pharmaceutical compositions |
US14/214,367 Abandoned US20140274996A1 (en) | 2013-03-15 | 2014-03-14 | Tazobactam and ceftolozane antibiotic compositions |
US14/214,221 Active US9320740B2 (en) | 2013-03-15 | 2014-03-14 | Ceftolozane-tazobactam pharmaceutical compositions |
US14/214,417 Abandoned US20140274997A1 (en) | 2013-03-15 | 2014-03-14 | Cephalosporin pharmaceutical compositions |
US14/214,212 Abandoned US20140274993A1 (en) | 2013-03-15 | 2014-03-14 | Ceftolozane-tazobactam pharmaceutical compositions |
US14/212,590 Abandoned US20140275000A1 (en) | 2013-03-15 | 2014-03-14 | Ceftolozane pharmaceutical compositions |
US14/212,781 Abandoned US20140274990A1 (en) | 2013-03-15 | 2014-03-14 | Ceftolozane pharmaceutical compositions |
US14/285,185 Active US8968753B2 (en) | 2013-03-15 | 2014-05-22 | Ceftolozane-tazobactam pharmaceutical compositions |
US14/522,893 Abandoned US20150045336A1 (en) | 2013-03-15 | 2014-10-24 | Tazobactam and ceftolozane antibiotic compositions |
US14/531,352 Abandoned US20150150883A1 (en) | 2013-03-15 | 2014-11-03 | Ceftolozane-tazobactam pharmaceutical compositions |
US15/071,530 Active US9925196B2 (en) | 2013-03-15 | 2016-03-16 | Ceftolozane-tazobactam pharmaceutical compositions |
US15/895,279 Abandoned US20180169106A1 (en) | 2013-03-15 | 2018-02-13 | Ceftolozane-tazobactam pharmaceutical compositions |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/213,532 Abandoned US20140274991A1 (en) | 2013-03-15 | 2014-03-14 | Ceftolozane pharmaceutical compositions |
US14/214,367 Abandoned US20140274996A1 (en) | 2013-03-15 | 2014-03-14 | Tazobactam and ceftolozane antibiotic compositions |
US14/214,221 Active US9320740B2 (en) | 2013-03-15 | 2014-03-14 | Ceftolozane-tazobactam pharmaceutical compositions |
US14/214,417 Abandoned US20140274997A1 (en) | 2013-03-15 | 2014-03-14 | Cephalosporin pharmaceutical compositions |
US14/214,212 Abandoned US20140274993A1 (en) | 2013-03-15 | 2014-03-14 | Ceftolozane-tazobactam pharmaceutical compositions |
US14/212,590 Abandoned US20140275000A1 (en) | 2013-03-15 | 2014-03-14 | Ceftolozane pharmaceutical compositions |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/285,185 Active US8968753B2 (en) | 2013-03-15 | 2014-05-22 | Ceftolozane-tazobactam pharmaceutical compositions |
US14/522,893 Abandoned US20150045336A1 (en) | 2013-03-15 | 2014-10-24 | Tazobactam and ceftolozane antibiotic compositions |
US14/531,352 Abandoned US20150150883A1 (en) | 2013-03-15 | 2014-11-03 | Ceftolozane-tazobactam pharmaceutical compositions |
US15/071,530 Active US9925196B2 (en) | 2013-03-15 | 2016-03-16 | Ceftolozane-tazobactam pharmaceutical compositions |
US15/895,279 Abandoned US20180169106A1 (en) | 2013-03-15 | 2018-02-13 | Ceftolozane-tazobactam pharmaceutical compositions |
Country Status (1)
Country | Link |
---|---|
US (12) | US20140274991A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8968753B2 (en) | 2013-03-15 | 2015-03-03 | Calixa Therapeutics, Inc. | Ceftolozane-tazobactam pharmaceutical compositions |
US9044485B2 (en) | 2013-03-15 | 2015-06-02 | Calixa Therapeutics, Inc. | Ceftolozane antibiotic compositions |
US9724353B2 (en) | 2011-09-09 | 2017-08-08 | Merck Sharp & Dohme Corp. | Methods for treating intrapulmonary infections |
US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US10376496B2 (en) | 2013-09-09 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
CN110314163A (en) * | 2018-03-30 | 2019-10-11 | 杭州森泽医药科技有限公司 | A kind of latamoxef sodium pharmaceutical composition and application |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE112008001301T5 (en) | 2007-05-14 | 2010-04-29 | Reserach Foundation Of State University Of New York | Induction of a physiological dispersion response in bacterial cells in a biofilm |
KR102143256B1 (en) * | 2012-09-27 | 2020-08-11 | 머크 샤프 앤드 돔 코포레이션 | Tazobactam arginine antibiotic compositions |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
Family Cites Families (266)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL37879A (en) | 1970-10-27 | 1974-12-31 | Ciba Geigy Ag | 3-unsubstituted cephalosporin derivatives,process for their manufacture and compositions containing them |
US4299829A (en) | 1976-03-12 | 1981-11-10 | Fujisawa Pharmaceutical Co., Ltd. | 2-Lower alkyl-7-substituted-2 or 3-cephem 4-carboxylic acid compounds |
PH17188A (en) | 1977-03-14 | 1984-06-14 | Fujisawa Pharmaceutical Co | New cephem and cepham compounds and their pharmaceutical compositions and method of use |
US4409217A (en) | 1977-03-14 | 1983-10-11 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
US4464369A (en) | 1977-03-14 | 1984-08-07 | Fujisawa Pharmaceutical Co., Ltd. | 7-Acylamino-3-cephem-4-carboxylic acid derivatives and pharmaceutical compositions |
US4496562A (en) | 1977-03-14 | 1985-01-29 | Fujisawa Pharmaceutical Co., Ltd. | 7-Substituted-3-cephem-4-carboxylic acid esters |
JPS543087A (en) | 1977-06-03 | 1979-01-11 | Fujisawa Pharmaceut Co Ltd | Preparation of cephalosporin compound |
GB1604738A (en) | 1977-07-28 | 1981-12-16 | Yamanouchi Pharma Co Ltd | 1,3-dithietane-2-carboxylic acid derivatives and the preparation thereof |
JPS609719B2 (en) | 1977-08-06 | 1985-03-12 | 武田薬品工業株式会社 | Cephalosporin derivatives and their production method |
US4370326A (en) | 1977-09-13 | 1983-01-25 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds and composition |
IT1192287B (en) | 1977-11-14 | 1988-03-31 | Fujisawa Pharmaceutical Co | PHARMACEUTICAL ACTION DERIVATIVES OF CEPHALOSPORANIC ACID AND RELATED PREPARATION PROCEDURE |
US4363807A (en) | 1978-04-06 | 1982-12-14 | Fujisawa Pharmaceutical Company, Limited | Cepham compounds |
SE7804231L (en) | 1978-04-14 | 1979-10-15 | Haessle Ab | Gastric acid secretion |
AR228726A1 (en) | 1978-05-26 | 1983-04-15 | Glaxo Group Ltd | PROCEDURE FOR THE PREPARATION OF ANTIBIOTIC (6R, 7R) -7 - ((Z) -2- (2-AMINOTIAZOL-4-IL) -2- (2-CARBOXIPROP-2-OXIIMINO) ACETAMIDO) -3- (1- PIRIDINIOMETIL) CEF-3-EM-4-CARBOXILATO |
US4264597A (en) | 1978-06-06 | 1981-04-28 | Masashi Hashimoto | Cephalosporin analogues and processes for the preparation thereof |
US4268509A (en) | 1978-07-10 | 1981-05-19 | Fujisawa Pharmaceutical Co., Ltd. | New cephem compounds and processes for preparation thereof |
US4284631A (en) | 1978-07-31 | 1981-08-18 | Fujisawa Pharmaceutical Co., Ltd. | 7-Substituted cephem compounds and pharmaceutical antibacterial compositions containing them |
US4305937A (en) | 1978-08-17 | 1981-12-15 | Fujisawa Pharmaceutical Co., Ltd. | 2-Lower alkyl-7-substituted-2 or 3-cephem-4-carboxylic acid compounds and antibacterial pharmaceutical compositions containing them |
US4703046A (en) | 1978-09-08 | 1987-10-27 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds and processes for preparation thereof |
EP0009671B1 (en) | 1978-09-12 | 1984-06-13 | Fujisawa Pharmaceutical Co., Ltd. | Starting compounds for preparing cephem compounds and processes for their preparation |
US4327093A (en) | 1978-10-24 | 1982-04-27 | Fujisawa Pharmaceutical Co., Ltd. | 3,7-Disubstituted-2 or 3-cephem-4-carboxylic acid compounds |
DE2945248A1 (en) | 1978-11-13 | 1980-05-22 | Fujisawa Pharmaceutical Co | CEPHEM COMPOUNDS, METHOD FOR THEIR PRODUCTION AND ANTIBACTERIAL PHARMACEUTICAL AGENTS CONTAINING THE SAME |
US4332798A (en) | 1978-12-29 | 1982-06-01 | Fujisawa Pharmaceutical Co., Ltd. | 7-Amino-thia-diazole oxyimino derivatives of cephem and cephem compounds |
US4390534A (en) | 1978-12-29 | 1983-06-28 | Fujisawa Pharmaceutical Co., Ltd. | Cephem and cepham compounds |
AU536842B2 (en) | 1978-12-29 | 1984-05-24 | Fujisawa Pharmaceutical Co., Ltd. | Cephalosporin antibiotics |
US4291031A (en) | 1979-02-19 | 1981-09-22 | Fujisawa Pharmaceutical Co., Ltd. | 3-Phosphonocephalosporanic acid derivatives, and pharmaceutical composition comprising the same |
US4339449A (en) | 1979-03-27 | 1982-07-13 | Fujisawa Pharmaceutical Company, Limited | Analogous compounds of cephalosporins, and pharmaceutical composition comprising the same |
FR2462439A1 (en) | 1979-07-26 | 1981-02-13 | Roussel Uclaf | NOVEL PROCESS FOR THE PREPARATION OF PRODUCTS DERIVED FROM 7 - / (2-ARYL) 2-HYDROXYIMINO ACETAMIDO / CEPHALOSPORANIC ACID |
DE3069560D1 (en) | 1979-09-03 | 1984-12-06 | Fujisawa Pharmaceutical Co | Cephem compounds, processes for their preparation and pharmaceutical compositions containing them |
US4332800A (en) | 1979-10-12 | 1982-06-01 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
US4338313A (en) | 1979-10-12 | 1982-07-06 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
US4381299A (en) | 1980-03-07 | 1983-04-26 | Fujisawa Pharmaceutical Co., Ltd. | 7-Amino-thiadiazole oxyimino derivatives of cephem and cepham compounds |
US4409215A (en) | 1979-11-19 | 1983-10-11 | Fujisawa Pharmaceutical Co., Ltd. | 7-Acylamino-3-substituted cephalosporanic acid derivatives and processes for the preparation thereof |
US4409214A (en) | 1979-11-19 | 1983-10-11 | Fujisawa Pharmaceutical, Co., Ltd. | 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof |
US4420477A (en) | 1979-11-30 | 1983-12-13 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
US4443443A (en) | 1979-12-17 | 1984-04-17 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
US4405617A (en) | 1980-02-11 | 1983-09-20 | Fujisawa Pharmaceutical Co., Ltd. | 3-(Propynyltetrazol)thiomethyl-3-cephems |
JPS56125392A (en) | 1980-03-06 | 1981-10-01 | Fujisawa Pharmaceut Co Ltd | Cepham and cephem compound and preparation thereof |
US4470980A (en) | 1980-03-07 | 1984-09-11 | Interx Research Corp. | Method of increasing oral absorption of β-lactam antibiotics |
JPS5711909A (en) | 1980-06-23 | 1982-01-21 | Shionogi & Co Ltd | Stable freeze-dried preparation of beta-lactam |
DE3173613D1 (en) | 1980-07-04 | 1986-03-13 | Fujisawa Pharmaceutical Co | 7-oxo-cephalosporins and 6-oxo-penicillins, their analogues and process for their preparation |
US4443444A (en) | 1980-08-11 | 1984-04-17 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
EP0156118A1 (en) | 1980-08-29 | 1985-10-02 | Fujisawa Pharmaceutical Co., Ltd. | New starting compounds for the preparation of cephem compounds and processes for preparation thereof |
US4416879A (en) | 1980-09-08 | 1983-11-22 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
GR78245B (en) | 1980-09-12 | 1984-09-26 | Ciba Geigy Ag | |
US4367228A (en) | 1980-10-29 | 1983-01-04 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compound and composition |
US4431642A (en) | 1980-12-01 | 1984-02-14 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
DK554481A (en) | 1980-12-15 | 1982-06-16 | Fujisawa Pharmaceutical Co | METHOD OF PREPARING CEPHALOSPORANIC ACID DERIVATIVES |
EP0055465B1 (en) | 1980-12-31 | 1989-08-23 | Fujisawa Pharmaceutical Co., Ltd. | 7-acylaminocephalosporanic acid derivatives and processes for the preparation thereof |
US4427677A (en) | 1980-12-31 | 1984-01-24 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
GR76342B (en) | 1981-02-02 | 1984-08-06 | Fujisawa Pharmaceutical Co | |
US4336253A (en) | 1981-03-11 | 1982-06-22 | Eli Lilly And Company | Cephalosporin antibiotics |
JPS6011917B2 (en) | 1981-04-09 | 1985-03-28 | 山之内製薬株式会社 | Novel cephalosporin compounds |
DE3118732A1 (en) | 1981-05-12 | 1982-12-02 | Hoechst Ag, 6000 Frankfurt | CEPHALOSPORINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION |
JPS57193489A (en) | 1981-05-21 | 1982-11-27 | Fujisawa Pharmaceut Co Ltd | Syn-isomer of 7-substituted-3-cephem-4-carboxylic acid ester and its preparation |
GR75487B (en) | 1981-06-22 | 1984-07-23 | Fujisawa Pharmaceutical Co | |
IE53429B1 (en) | 1981-08-03 | 1988-11-09 | Fujisawa Pharmaceutical Co | New cephem compounds and processes for preparation thereof |
US4577014A (en) | 1981-09-08 | 1986-03-18 | Eli Lilly And Company | Thieno and furopyridinium-substituted cephalosporins |
US4436912A (en) | 1981-09-08 | 1984-03-13 | Eli Lilly And Company | 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido cephalosporin antibiotics and intermediates therefor |
US4430499A (en) | 1981-09-08 | 1984-02-07 | Eli Lilly And Company | 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido]cephalosporin antibiotics |
JPS5859991A (en) | 1981-09-14 | 1983-04-09 | Fujisawa Pharmaceut Co Ltd | Novel cephem compound and its preparation |
US4521413A (en) | 1981-09-14 | 1985-06-04 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
US4450270A (en) | 1981-10-02 | 1984-05-22 | Eli Lilly And Company | Dioximino cephalosporin antibiotics |
US4402955A (en) | 1981-10-02 | 1983-09-06 | Eli Lilly And Company | Dioximino cephalosporin antibiotics |
US4501739A (en) | 1982-01-19 | 1985-02-26 | Eli Lilly And Company | Thieno and furopyridinium-substituted cephalosporins |
DE3207840A1 (en) | 1982-03-04 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | "CEPHALOSPORINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF" |
JPS58154547A (en) | 1982-03-09 | 1983-09-14 | Nippon Shinyaku Co Ltd | Stabilization of azulene derivative |
US4640915A (en) | 1982-03-29 | 1987-02-03 | Fujisawa Pharmaceutical Co., Ltd. | 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid derivatives |
AU541028B2 (en) | 1982-06-21 | 1984-12-13 | Taiho Pharmaceutical Co., Ltd. | 6-unsubstituted penicillin derivatives |
JPS58225091A (en) | 1982-06-21 | 1983-12-27 | Taiho Yakuhin Kogyo Kk | Penicillin derivative and its preparation |
US4563449A (en) | 1982-07-19 | 1986-01-07 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
US4546101A (en) | 1982-09-10 | 1985-10-08 | Fujisawa Pharmaceutical Co., Ltd. | New cephem compounds useful for treating infectious diseases in human being and animals and processes for preparation thereof |
GB8323034D0 (en) | 1983-08-26 | 1983-09-28 | Fujisawo Pharmaceutical Co Ltd | 7-substituted-3-vinyl-3-cephem compounds |
US4609730A (en) | 1982-11-22 | 1986-09-02 | Fujisawa Pharmaceutical Co., Ltd. | 7-[substituted imino-2-(2-aminothiazol-4-yl)-acetamido]-3(2,2-dihalovinyl or ethynyl)-3-cephem-4-carboxylic acid (syn isomers), having antimicrobial activities |
GR79043B (en) | 1982-12-06 | 1984-10-02 | Fujisawa Pharmaceutical Co | |
US4608373A (en) | 1982-12-13 | 1986-08-26 | Yamanouchi Pharmaceutical Co., Ltd. | Cephem compounds |
US4487768A (en) | 1982-12-22 | 1984-12-11 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
US4463003A (en) | 1982-12-22 | 1984-07-31 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
DE3247613A1 (en) | 1982-12-23 | 1984-07-05 | Hoechst Ag, 6230 Frankfurt | CEPHALOSPORINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION |
US4562073A (en) | 1982-12-24 | 1985-12-31 | Taiho Pharmaceutical Company Limited | Penicillin derivatives |
US4499088A (en) | 1983-01-04 | 1985-02-12 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
DE3316798A1 (en) | 1983-05-07 | 1984-11-08 | Hoechst Ag, 6230 Frankfurt | METHOD FOR PRODUCING CEPHEM COMPOUNDS |
FR2550200B1 (en) | 1983-08-01 | 1988-04-08 | Fujisawa Pharmaceutical Co | PROCESS FOR THE PREPARATION OF CEPHEM COMPOUNDS WITH ANTIMICROBIAL ACTIVITY AND NOVEL PRODUCTS THUS OBTAINED |
JPS6045514A (en) | 1983-08-22 | 1985-03-12 | Shionogi & Co Ltd | Stable antibacterial lyophilized pharmactical preparation |
DE3409431A1 (en) | 1983-10-08 | 1985-04-18 | Hoechst Ag, 6230 Frankfurt | CEPHALOSPORINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION |
EP0137442A3 (en) | 1983-10-08 | 1986-01-15 | Hoechst Aktiengesellschaft | Cephalosporin derivatives and process for their preparation |
US4690921A (en) | 1983-10-11 | 1987-09-01 | Yamanouchi Pharmaceutical Co., Ltd. | Cephalosporin compounds and salts thereof |
ZA847926B (en) | 1983-10-17 | 1986-05-28 | Lilly Co Eli | 3-bicyclicpyridinium-methyl cephalosporins |
US4748172A (en) | 1983-10-17 | 1988-05-31 | Eli Lilly And Company | 3-bicyclicpyridinium-methyl cephalosporins |
US4692443A (en) | 1983-10-17 | 1987-09-08 | Eli Lilly And Company | 3-bicyclicpyridinium-methyl cephalosporins |
GB8329030D0 (en) | 1983-10-31 | 1983-11-30 | Fujisawa Pharmaceutical Co | Cephem compounds |
GB8401093D0 (en) | 1984-01-16 | 1984-02-15 | Fujisawa Pharmaceutical Co | Cephem compounds |
JPS60169486A (en) | 1984-02-10 | 1985-09-02 | Yamanouchi Pharmaceut Co Ltd | Preparation of 7-amino-3-substituted methyl-3-cephem-4- carboxylic acid and lower alkylsilyl derivative thereof |
GB8406231D0 (en) | 1984-03-09 | 1984-04-11 | Fujisawa Pharmaceutical Co | Cephem compounds |
JPS60214792A (en) | 1984-04-06 | 1985-10-28 | Taiho Yakuhin Kogyo Kk | Penamylacid ester derivative |
US4705851A (en) | 1984-09-28 | 1987-11-10 | Fujisawa Pharmaceutical Co., Ltd. | Process for the preparation of 3-phosphoniummethyl-3-cephem compounds |
US4761410A (en) | 1985-01-14 | 1988-08-02 | Fujisawa Pharmaceutical Co., Ltd. | Cephem Compounds |
NZ214864A (en) | 1985-01-21 | 1988-04-29 | Sankei Yakuhin Kk | #b#-lactam compounds |
GB8504072D0 (en) | 1985-02-18 | 1985-03-20 | Fujisawa Pharmaceutical Co | Cephem compounds |
JPS62103092A (en) | 1985-07-18 | 1987-05-13 | Sagami Chem Res Center | Beta-lactam derivative |
JPS6230789A (en) | 1985-08-01 | 1987-02-09 | Yamanouchi Pharmaceut Co Ltd | 7-formylaminocephalosporin compound and production thereof |
CN86107947A (en) | 1985-11-22 | 1987-05-27 | 藤沢药品工业株式会社 | New cephem compounds and preparation method thereof |
US5194432A (en) | 1985-11-22 | 1993-03-16 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
US4808617A (en) | 1985-12-18 | 1989-02-28 | Bristol-Myers Company | Lyophilized or precipitated cephalosporin zwitterion and salt combination |
JPS62158290A (en) | 1985-12-28 | 1987-07-14 | Banyu Pharmaceut Co Ltd | Novel cephalosporin derivative |
EP0237735B1 (en) | 1986-03-17 | 1994-03-30 | Fujisawa Pharmaceutical Co., Ltd. | 3,7-Disubstituted-3-cephem compounds and process for production of the same |
JP2690009B2 (en) | 1986-07-10 | 1997-12-10 | エーザイ 株式会社 | Cefalosporin injection |
US4833134A (en) | 1986-08-19 | 1989-05-23 | Takeda Chemical Industries, Ltd. | Cephem compounds |
JPS6351388A (en) | 1986-08-22 | 1988-03-04 | Teijin Ltd | Cephalosporin derivative, production thereof and composition having antimicrobial activity |
JPS6351389A (en) | 1986-08-22 | 1988-03-04 | Teijin Ltd | Cephalosporin derivative, production thereof and composition having antimicrobial activity |
US5162520A (en) | 1986-09-22 | 1992-11-10 | Fujisawa Pharmaceutical Co., Ltd. | Intermediates for cephem compounds |
CA1293719C (en) | 1986-09-22 | 1991-12-31 | Takao Takaya | Cephem compounds and processes for preparation thereof |
US4882434A (en) | 1986-10-29 | 1989-11-21 | Takeda Chemical Industries, Ltd. | Gamma-lactonecarboxylic acid derivatives and their use as antibacterial agents or intermediates |
KR880006244A (en) | 1986-11-24 | 1988-07-22 | 후지사와 도모 기찌 로 | 3-Pyrrolidinylthio-1-azabibischloro [3.2.0] hapt2-ene-2-carboxylic acid compound and preparation method thereof |
EP0272455B1 (en) | 1986-11-24 | 1993-02-10 | Fujisawa Pharmaceutical Co., Ltd. | 3-Pyrrolidinylthio-1-azabicyclo [3.2.0] hept-2-ene-2-carboxylic acid compounds |
AU1630988A (en) | 1987-05-30 | 1988-12-01 | Kyoto Pharmaceutical Industries, Ltd. | Cephalosporin compound and pharmaceutical composition thereof |
IE61679B1 (en) | 1987-08-10 | 1994-11-16 | Fujisawa Pharmaceutical Co | Water-soluble antibiotic composition and water-soluble salts of new cephem compounds |
US5138066A (en) | 1987-08-14 | 1992-08-11 | Hoffmann-La Roche, Inc. | Intermediates for cephalosporins with sulfur-containing oxyimino side chain |
EP0303172A3 (en) | 1987-08-14 | 1991-05-15 | F. Hoffmann-La Roche Ag | Oxyimino-cephalosporins |
US5073550A (en) | 1987-08-14 | 1991-12-17 | Hoffmann-La Roche Inc. | Cephalosphorins with sulfur-containing oxyimino side chain |
ZA885709B (en) | 1987-08-19 | 1989-04-26 | Fujisawa Pharmaceutical Co | Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid(syn isomer) |
US5663163A (en) | 1987-09-07 | 1997-09-02 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds and processes for preparation thereof |
US5210080A (en) | 1987-09-07 | 1993-05-11 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
IE63094B1 (en) | 1987-09-14 | 1995-03-22 | Fujisawa Pharmaceutical Co | Cephem compound and a process for preparation thereof |
DK637888A (en) | 1987-11-24 | 1989-05-25 | Hoffmann La Roche | carboxylic esters |
GB8804058D0 (en) | 1988-02-22 | 1988-03-23 | Fujisawa Pharmaceutical Co | 3-alkenyl-1-azabicyclo(3 2 0)hept-2-ene-2-carboxylic acid compounds |
JP2648750B2 (en) | 1988-03-02 | 1997-09-03 | 大塚化学株式会社 | Method for producing β-lactam derivative |
US5173485A (en) | 1988-03-09 | 1992-12-22 | Fujisawa Pharmaceutical Company, Ltd. | Cephem compounds |
US5336768A (en) | 1988-05-24 | 1994-08-09 | Hoffmann-La Roche Inc. | Antibacterial cephalosporin compounds |
CS273349B2 (en) | 1988-03-31 | 1991-03-12 | Hoffmann La Roche | Method of cephalosporin's new derivatives production |
KR900006811B1 (en) | 1988-05-11 | 1990-09-21 | 주식회사 럭 키 | Cephalosphorin derivatives and its process |
US4963544A (en) | 1988-05-23 | 1990-10-16 | Fujisawa Pharmaceutical Company, Ltd. | 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds |
US5244890A (en) | 1988-06-06 | 1993-09-14 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
EP0366189A3 (en) | 1988-10-24 | 1992-01-02 | Norwich Eaton Pharmaceuticals, Inc. | Novel antimicrobial lactam-quinolones |
JP2785195B2 (en) | 1989-01-11 | 1998-08-13 | ソニー株式会社 | Optical encoder for disk drive |
GB8905301D0 (en) | 1989-03-08 | 1989-04-19 | Fujisawa Pharmaceutical Co | New cephem compound and a process for preparation thereof |
US5081116A (en) | 1989-04-12 | 1992-01-14 | Yamanouchi Pharmaceutical Co., Ltd. | Cephalosporin derivatives |
US5102877A (en) | 1989-04-28 | 1992-04-07 | Fujisawa Pharmaceutical Co., Ltd. | 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds |
NO903360L (en) | 1989-08-11 | 1991-02-12 | Ici Pharma | ANTIBIOTIC COMPOUNDS. |
GB8923844D0 (en) | 1989-10-23 | 1989-12-13 | Fujisawa Pharmaceutical Co | Carbapenem compounds |
US5215982A (en) | 1989-11-10 | 1993-06-01 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
US4982596A (en) | 1990-01-26 | 1991-01-08 | Buell Industries, Inc. | Die for manufacturing a fastener blank |
KR910015587A (en) | 1990-02-27 | 1991-09-30 | 후지사와 토모키치로 | Cefem compound |
US5095012A (en) | 1990-08-23 | 1992-03-10 | Bristol-Myers Squibb Company | Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof |
US5234920A (en) | 1990-08-23 | 1993-08-10 | Bristol-Myers Squibb Company | Antibiotic C-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof |
US5286721A (en) | 1990-10-15 | 1994-02-15 | Fujisawa Pharmaceutical Co., Ltd. | 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds |
GB9023479D0 (en) | 1990-10-29 | 1990-12-12 | Fujisawa Pharmaceutical Co | New cephem compounds and processes for preparation thereof |
US5281589A (en) | 1991-06-15 | 1994-01-25 | Cheil Foods & Chemicals, Inc. | 3-fused pyridiniummethyl cephalosporins |
US5523400A (en) | 1993-04-16 | 1996-06-04 | Hoffmann-La Roche Inc. | Cephalosporin antibiotics |
KR100194994B1 (en) | 1993-06-05 | 1999-06-15 | 손경식 | New cefem compound |
EP0678095A1 (en) | 1993-11-06 | 1995-10-25 | Taiho Pharmaceutical Co., Ltd. | Crystalline penicillin derivative, and its production and use |
EP0664117A1 (en) | 1994-01-25 | 1995-07-26 | F. Hoffmann-La Roche Ag | Liposome solutions |
TW293010B (en) | 1994-04-20 | 1996-12-11 | Hui-Po Wang | Method for preparing cephalosporin derivatives |
KR100248851B1 (en) | 1994-08-16 | 2000-04-01 | 이치로 키타사토 | A novel cephem derivative |
DE4440141A1 (en) | 1994-11-10 | 1996-05-15 | Hoechst Ag | Novel crystalline cephem acid addition salts and process for their preparation |
JPH09110877A (en) | 1995-10-17 | 1997-04-28 | Katayama Seiyakushiyo:Kk | Cephem compound, its production and antibacterial agent containing the compound |
ATE341554T1 (en) | 1996-04-04 | 2006-10-15 | Shionogi & Co | CEPHEM COMPOUNDS AND MEDICATIONS CONTAINING THESE COMPOUNDS |
AUPN955596A0 (en) | 1996-04-30 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
WO1999028308A1 (en) | 1997-11-29 | 1999-06-10 | Truett William L | Antibiotics and process for preparation |
US6235311B1 (en) | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
CA2319495A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
WO2000004915A1 (en) | 1998-07-23 | 2000-02-03 | Intrabiotics Pharmaceuticals, Inc. | Compositions and methods for the treatment or prevention of pulmonary infections |
TW526202B (en) | 1998-11-27 | 2003-04-01 | Shionogi & Amp Co | Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity |
CN1109688C (en) | 1999-01-12 | 2003-05-28 | 中国药品生物制品检定所 | Preparation and application of tazobactam semihydrate |
US6207661B1 (en) | 1999-02-22 | 2001-03-27 | Baxter International Inc. | Premixed formulation of piperacillin sodium and tazobactam sodium injection |
TWI233805B (en) | 1999-07-01 | 2005-06-11 | Fujisawa Pharmaceutical Co | Stabilized pharmaceutical composition in lyophilized form as antifungal agent |
BR0013366A (en) | 1999-08-16 | 2002-07-23 | Revaax Pharmaceuticals Llc | Methods to treat a behavioral disorder, a human patient, prostate disease, anxiety and cognitive disorders in a human patient afflicted with a condition or willing to develop a condition distinguished at least in part by the concentration of abnormal extracellular glutamate in the brain or in other nervous tissue, behavioral disorder in human, canine, feline and equine species and a patient afflicted with or willing to develop a disease comprising abnormally high glutamate concentrations in neuronal tissue or elevated naaladase levels in prostate tissue and with multiple sclerosis and to enhance cognitive function, pharmaceutical formulation and uses of an inhibitor of peptidase activity of an acidic dipeptidase bound in n-acetylated alpha and a beta-lactam compound |
WO2001080858A1 (en) | 2000-04-24 | 2001-11-01 | Daiichi Pharmaceutical Co., Ltd. | Stable liquid preparation |
JP3743822B2 (en) | 2000-08-11 | 2006-02-08 | 大塚化学ホールディングス株式会社 | Penicillin crystals and production method thereof |
JP3743823B2 (en) | 2000-08-11 | 2006-02-08 | 大塚化学ホールディングス株式会社 | Penicillin crystals and production method thereof |
US6599893B2 (en) | 2000-08-29 | 2003-07-29 | Essential Therapeutics, Inc. | Cephalosporin antibiotics and prodrugs thereof |
JP3306473B1 (en) | 2001-05-01 | 2002-07-24 | 大塚化学株式会社 | Anhydrous crystal of β-lactam compound and method for producing the same |
DE60209341T2 (en) | 2001-05-01 | 2006-08-03 | Astellas Pharma Inc. | Cephem CONNECTIONS |
JP2002338578A (en) | 2001-05-14 | 2002-11-27 | Otsuka Chem Co Ltd | HYDRATE CRYSTAL OF beta-LACTAM COMPOUND |
US7166626B2 (en) | 2001-06-18 | 2007-01-23 | Revaax Pharmaceuticals, Llc | Therapeutic treatment for sexual dysfunction |
TWI335332B (en) | 2001-10-12 | 2011-01-01 | Theravance Inc | Cross-linked vancomycin-cephalosporin antibiotics |
US7378408B2 (en) | 2001-11-30 | 2008-05-27 | Pfizer Inc. | Methods of treatment and formulations of cephalosporin |
WO2003066053A1 (en) | 2002-02-07 | 2003-08-14 | Rutgers, The State University | Antibiotic polymers |
TW200305422A (en) | 2002-03-18 | 2003-11-01 | Shionogi & Co | Broad spectrum cefem compounds |
WO2003099858A1 (en) | 2002-05-24 | 2003-12-04 | Theravance, Inc. | Cross-linked glycopeptide-cephalosporin antibiotics |
AU2002309162A1 (en) | 2002-06-07 | 2003-12-22 | Orchid Chemicals And Pharmaceuticals Limited | Process for preparation of penam derivatives from cepham derivatives |
WO2004019901A2 (en) | 2002-08-30 | 2004-03-11 | Orchid Chemicals & Pharmaceuticals Ltd. | Sustained release pharmaceutical composition |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
JP4448821B2 (en) | 2002-10-30 | 2010-04-14 | アステラス製薬株式会社 | Cephem compound |
AU2003274518A1 (en) | 2002-11-01 | 2004-05-25 | Orchid Chemicals And Pharmaceuticals Ltd | A process for the preparation of benzyl 2-oxo-4- (heteroaryl) dithio-alpha-isoprenyl-1- azetidineazetate derivatives |
EP1908850B1 (en) | 2002-11-22 | 2012-01-04 | The Johns Hopkins University | Target for therapy of cognitive impairment |
DE10304403A1 (en) | 2003-01-28 | 2004-08-05 | Röhm GmbH & Co. KG | Process for the preparation of an oral dosage form with immediate disintegration and drug release |
JP4288086B2 (en) | 2003-02-25 | 2009-07-01 | 大日本印刷株式会社 | Exposure equipment |
WO2004098643A1 (en) | 2003-04-14 | 2004-11-18 | Wyeth Holdings Corporation | Compositions containing piperacillin and tazobactam useful for injection |
PL1468697T3 (en) | 2003-04-14 | 2008-05-30 | Wyeth Corp | Compositions containing piperacillin and tazobactam useful for injection |
AU2003902380A0 (en) | 2003-05-16 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
ATE450540T1 (en) | 2003-05-23 | 2009-12-15 | Theravance Inc | CROSS-LINKED GLYCOPEPTIDE CEPHALOSPORIN ANTIBIOTICS |
EP1644382B1 (en) | 2003-07-11 | 2008-03-05 | Theravance, Inc. | Cross-linked glycopeptide-cephalosporin antibiotics |
US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
US7589233B2 (en) | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
US7273935B2 (en) | 2003-08-21 | 2007-09-25 | Orchid Chemicals & Pharmaceuticals, Ltd. | Process for the preparation of 3-methylcepham derivatives |
DE602004026451D1 (en) | 2003-09-18 | 2010-05-20 | Astellas Pharma Inc | Cephem CONNECTIONS |
FR2860235A1 (en) | 2003-09-29 | 2005-04-01 | Yang Ji Chemical Company Ltd | USE OF A COMPOUND OF FORMULA (I) INHIBITOR OF AROMATASE FOR THERAPEUTIC PURPOSES AND COMPOUNDS OF FORMULA (I) AS SUCH |
TW200523264A (en) | 2003-10-09 | 2005-07-16 | Otsuka Chemical Co Ltd | CMPB crystal and method for producing the same |
TW200519119A (en) | 2003-10-10 | 2005-06-16 | Otsuka Chemical Co Ltd | PENAM crystal and process for producing the same |
JP4535366B2 (en) | 2003-12-03 | 2010-09-01 | 塩野義製薬株式会社 | Method for producing cephem agent |
EP1711178A1 (en) | 2004-01-30 | 2006-10-18 | Wyeth | Compositions substantially free of galactomannan containing piperacillin and tazobactam |
WO2005078848A2 (en) | 2004-02-11 | 2005-08-25 | University Of Tennessee Research Foundation | Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes |
CA2557988A1 (en) | 2004-03-05 | 2005-09-15 | Shionogi & Co., Ltd. | 3-pyridinium methylcephem compound |
US7417143B2 (en) | 2004-04-07 | 2008-08-26 | Orchid Chemicals & Pharmaceuticals Limited | Process for the preparation of Tazobactam in pure form |
JP2008516967A (en) | 2004-10-14 | 2008-05-22 | ワイス | Composition comprising piperacillin, tazobactam and aminocarboxylic acid in a dilute solution of sodium lactate |
US20060099253A1 (en) | 2004-10-20 | 2006-05-11 | Wyeth | Antibiotic product formulation |
US20060173177A1 (en) | 2005-01-28 | 2006-08-03 | Gego Csaba L | Process for preparation of penam derivatives |
EP1848413B1 (en) | 2005-02-14 | 2014-04-09 | Venus Remedies Limited | Parenteral combination therapy for infective conditions with drug resistant bacterium |
KR100822519B1 (en) | 2005-02-15 | 2008-04-16 | 주식회사종근당 | Gastric-retentive controlled release mono-matrix tablet |
AU2006339311A1 (en) | 2005-06-07 | 2007-09-07 | Foamix Ltd. | Antibiotic kit and composition and uses thereof |
ITMI20051630A1 (en) | 2005-09-02 | 2007-03-03 | Acs Dobfar Spa | INJECTABLE STERILE PHARMACEUTICAL FORMULATION CONTAINING AT LEAST TWO ACTIVE PRINCIPLES |
EP1928410A2 (en) | 2005-09-29 | 2008-06-11 | Nektar Therapeutics | Antibiotic formulations, unit doses, kits, and methods |
EP1787641A1 (en) | 2005-11-22 | 2007-05-23 | Helm AG | Tazobactam-piperacillin lyophilisate |
ATE485043T1 (en) | 2005-12-05 | 2010-11-15 | Sandoz Ag | METHOD FOR PRODUCING LYOPHILIZED PIPERACILLIN SODIUM IN COMBINATION WITH TAZOBACTAM SODIUM, WITH IMPROVED STABILITY AFTER RECONSTITUTION |
WO2007086014A1 (en) | 2006-01-25 | 2007-08-02 | Jegannathan Srinivas | Formulation comprising cefpirome, tazobactam and linezolid |
WO2007086013A1 (en) | 2006-01-25 | 2007-08-02 | Jegannathan Srinivas | Formulation comprising of ceftazidime, tazobactam and linezolid |
WO2007086011A1 (en) | 2006-01-25 | 2007-08-02 | Jegannathan Srinivas | Formulation comprising cefepime, tazobactam and linezolid |
WO2008075207A2 (en) | 2006-04-04 | 2008-06-26 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
WO2007129176A2 (en) | 2006-04-28 | 2007-11-15 | Wockhardt Ltd | Improvements in therapy for treating resistant bacterial infections |
WO2007145868A1 (en) | 2006-06-07 | 2007-12-21 | Wyeth | Treating cystic fibrosis with antibiotics via an aerosol drug |
US20070286818A1 (en) | 2006-06-07 | 2007-12-13 | Wyeth | Treating cystic fibrosis with antibiotics via an aerosol drug |
US20070286817A1 (en) | 2006-06-07 | 2007-12-13 | Wyeth | Treating cystic fibrosis with antibiotics via a swirler delivery |
WO2007145866A1 (en) | 2006-06-07 | 2007-12-21 | Wyeth | Treating cystic fibrosis with antibiotics via a swirler delivery |
EP2046802B1 (en) | 2006-07-12 | 2013-08-21 | Allecra Therapeutics GmbH | 2-substituted methyl penam derivatives |
CN101129381B (en) | 2006-08-25 | 2012-02-01 | 天津和美生物技术有限公司 | Antibiotic compound containing beta-lactam antibiotic and ion chelating agent |
CN101129382B (en) | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | Antibiotic compound containing beta-lactam antibiotic and buffering component |
CN101129383B (en) | 2006-08-25 | 2014-04-02 | 天津和美生物技术有限公司 | Antibiotic compound containing aminoglycoside antibiotic |
NZ575435A (en) | 2006-09-07 | 2012-01-12 | Merial Ltd | Soft chewable, tablet, and long-acting injectable veterinary antibiotic formulations |
US20080103121A1 (en) | 2006-10-30 | 2008-05-01 | Gole Dilip J | Cephalosporin derivative formulation |
FI119678B (en) | 2006-11-28 | 2009-02-13 | Ipsat Therapies Oy | Use of beta-lactamase |
JP5324463B2 (en) | 2006-12-10 | 2013-10-23 | チョンシー ユー | Transdermal delivery system for β-lactam antibiotics |
DE102007009242A1 (en) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets with enteric-coated matix |
WO2008113177A1 (en) | 2007-03-20 | 2008-09-25 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
ITMI20070568A1 (en) | 2007-03-22 | 2008-09-23 | Acs Dobfar Spa | INJECTABLE STERILE PHARMACEUTICAL COMOSIATION HAVING PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM AS ACTIVE PRINCIPLES |
US20090098088A1 (en) | 2007-10-10 | 2009-04-16 | The Procter & Gamble Company | Methods And Kits For The Treatment Of Diverticular Conditions |
US8673970B2 (en) | 2008-02-21 | 2014-03-18 | Sequoia Pharmaceuticals, Inc. | HIV protease inhibitor and cytochrome p450 inhibitor combinations |
JP2011514902A (en) | 2008-03-04 | 2011-05-12 | エラン・ファルマ・インターナショナル・リミテッド | Stable liquid formulations of anti-infectives and controlled anti-infective regimens |
ITPI20080025A1 (en) | 2008-03-31 | 2009-10-01 | Italmed S R L | COMPOSITION FOR DENTAL USE FOR THE TREATMENT OF PERIMPLANTS |
WO2009134948A1 (en) | 2008-05-01 | 2009-11-05 | The Procter & Gamble Company | Methods and kits for the treatment of inflammatory bowel disorder conditions |
WO2010014285A1 (en) | 2008-07-30 | 2010-02-04 | Estabrook Pharmaceuticals, Inc. | Compositions including clavulanic acid and related methods of use |
CN101434610B (en) | 2008-12-19 | 2011-07-20 | 齐鲁天和惠世制药有限公司 | Penam iodide, preparation and use thereof |
AU2010257905B2 (en) | 2009-06-10 | 2016-11-10 | Techfields Biochem Co., Ltd. | High penetration compositions or prodrugs of antimicrobials and antimicrobial-related compounds |
JP2013500974A (en) | 2009-07-28 | 2013-01-10 | アナコール ファーマシューティカルズ,インコーポレイテッド | Trisubstituted boron-containing molecules |
CN101696212B (en) | 2009-08-28 | 2012-01-11 | 海南美大制药有限公司 | High-purity tazobactam sodium compound |
EP2536408A1 (en) | 2010-02-16 | 2012-12-26 | Wockhardt Research Centre | Efflux pump inhibitors |
US20130203726A1 (en) | 2010-03-09 | 2013-08-08 | Terry Roemer | FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS |
EP2555767A4 (en) | 2010-04-06 | 2013-08-28 | Prescience Labs Llc | Methods of treatment using 3-bromopyruvate and other selective inhibitors of atp production |
CN102020663B (en) | 2010-11-24 | 2013-04-03 | 山东鑫泉医药有限公司 | Tazobactam synthesis method |
CN102382123A (en) | 2011-03-10 | 2012-03-21 | 海南美好西林生物制药有限公司 | Preparation method of tazobactam sodium |
AU2011373912B2 (en) | 2011-07-26 | 2016-09-29 | Wockhardt Limited | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
PL2748165T3 (en) | 2011-08-27 | 2017-05-31 | Wockhardt Limited | 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections. |
JP6151257B2 (en) | 2011-09-09 | 2017-06-21 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Treatment of pulmonary infections |
US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
TW201343645A (en) | 2012-03-30 | 2013-11-01 | Cubist Pharm Inc | 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors |
SG11201406120SA (en) | 2012-03-30 | 2014-10-30 | Cubist Pharm Inc | ISOXAZOLE β-LACTAMASE INHIBITORS |
US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
US8809314B1 (en) | 2012-09-07 | 2014-08-19 | Cubist Pharmacueticals, Inc. | Cephalosporin compound |
KR102143256B1 (en) | 2012-09-27 | 2020-08-11 | 머크 샤프 앤드 돔 코포레이션 | Tazobactam arginine antibiotic compositions |
US8476425B1 (en) | 2012-09-27 | 2013-07-02 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine compositions |
US9872906B2 (en) * | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US20140274991A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Ceftolozane pharmaceutical compositions |
KR102226197B1 (en) | 2013-03-15 | 2021-03-11 | 머크 샤프 앤드 돔 코포레이션 | Ceftolozane antibiotic compositions |
US20150072968A1 (en) * | 2013-09-09 | 2015-03-12 | Calixa Therapeutics, Inc. | Treating Infections with Ceftolozane/Tazobactam in Subjects Having Impaired Renal Function |
US20160228448A1 (en) * | 2013-09-27 | 2016-08-11 | Merck Sharp & Dohme Corp. | Solid Forms of Ceftolozane |
US8906898B1 (en) * | 2013-09-27 | 2014-12-09 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
-
2014
- 2014-03-14 US US14/213,532 patent/US20140274991A1/en not_active Abandoned
- 2014-03-14 US US14/214,367 patent/US20140274996A1/en not_active Abandoned
- 2014-03-14 US US14/214,221 patent/US9320740B2/en active Active
- 2014-03-14 US US14/214,417 patent/US20140274997A1/en not_active Abandoned
- 2014-03-14 US US14/214,212 patent/US20140274993A1/en not_active Abandoned
- 2014-03-14 US US14/212,590 patent/US20140275000A1/en not_active Abandoned
- 2014-03-14 US US14/212,781 patent/US20140274990A1/en not_active Abandoned
- 2014-05-22 US US14/285,185 patent/US8968753B2/en active Active
- 2014-10-24 US US14/522,893 patent/US20150045336A1/en not_active Abandoned
- 2014-11-03 US US14/531,352 patent/US20150150883A1/en not_active Abandoned
-
2016
- 2016-03-16 US US15/071,530 patent/US9925196B2/en active Active
-
2018
- 2018-02-13 US US15/895,279 patent/US20180169106A1/en not_active Abandoned
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9724353B2 (en) | 2011-09-09 | 2017-08-08 | Merck Sharp & Dohme Corp. | Methods for treating intrapulmonary infections |
US10028963B2 (en) | 2011-09-09 | 2018-07-24 | Merck Sharp & Dohme Corp. | Methods for treating intrapulmonary infections |
US8968753B2 (en) | 2013-03-15 | 2015-03-03 | Calixa Therapeutics, Inc. | Ceftolozane-tazobactam pharmaceutical compositions |
US9044485B2 (en) | 2013-03-15 | 2015-06-02 | Calixa Therapeutics, Inc. | Ceftolozane antibiotic compositions |
US9320740B2 (en) | 2013-03-15 | 2016-04-26 | Merck Sharp & Dohme Corp. | Ceftolozane-tazobactam pharmaceutical compositions |
US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US9925196B2 (en) | 2013-03-15 | 2018-03-27 | Merck Sharp & Dohme Corp. | Ceftolozane-tazobactam pharmaceutical compositions |
US10420841B2 (en) | 2013-03-15 | 2019-09-24 | Merck, Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US11278622B2 (en) | 2013-03-15 | 2022-03-22 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US10376496B2 (en) | 2013-09-09 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
US10933053B2 (en) | 2013-09-09 | 2021-03-02 | Merck Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
CN110314163A (en) * | 2018-03-30 | 2019-10-11 | 杭州森泽医药科技有限公司 | A kind of latamoxef sodium pharmaceutical composition and application |
Also Published As
Publication number | Publication date |
---|---|
US8968753B2 (en) | 2015-03-03 |
US20180169106A1 (en) | 2018-06-21 |
US9320740B2 (en) | 2016-04-26 |
US20140274991A1 (en) | 2014-09-18 |
US9925196B2 (en) | 2018-03-27 |
US20140275000A1 (en) | 2014-09-18 |
US20140274993A1 (en) | 2014-09-18 |
US20140274998A1 (en) | 2014-09-18 |
US20140274997A1 (en) | 2014-09-18 |
US20140274996A1 (en) | 2014-09-18 |
US20140262868A1 (en) | 2014-09-18 |
US20150045336A1 (en) | 2015-02-12 |
US20150150883A1 (en) | 2015-06-04 |
US20160193221A1 (en) | 2016-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20140274990A1 (en) | Ceftolozane pharmaceutical compositions | |
US20140274994A1 (en) | Stabilizing ceftolozane | |
US11278622B2 (en) | Ceftolozane antibiotic compositions | |
AU2015200599B2 (en) | Ceftolozane Antibiotic Compositions | |
NZ711823B2 (en) | Ceftolozane antibiotic compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CUBIST PHARMACEUTICALS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TERRACCIANO, JOSEPH;DAMOUR, NICOLE MILLER;REEL/FRAME:032552/0473 Effective date: 20140326 |
|
AS | Assignment |
Owner name: CALIXA THERAPEUTICS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CUBIST PHARMACEUTICALS, INC.;REEL/FRAME:033972/0841 Effective date: 20140603 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CALIXA THERAPEUTICS, INC.;REEL/FRAME:037198/0658 Effective date: 20150610 |